Jean-Bernard Durand, MD, FACC, FACP, FCCP, FHFSA, FAHA, FHRS, FESC

Department of Cardiology, Division of Internal Medicine

About Dr. Jean-Bernard Durand

Dr. Durand completed training in clinical and basic science. While completing his residency in internal medicine, at Loyola University School of Medicine in Chicago. He completed an American Heart Association/Bugher Foundation Fellowship in Molecular Biology investigating Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy. He was awarded a Robert Woods Johnson Fellowship at Baylor College of Medicine in Molecular Genetics. This body of work lead to Localization of a gene to Chromosome 1q32 and Identification of the gene as Troponin, one of the first genes for Familial dilated Cardiomyopathy.

After completion of his clinical fellowship at Baylor College of Medicine, He also completed clinical fellowship in Immunology/Advanced Heart Failure/ Circulatory Support and Cardiac Transplantation. He served as Assistant Medical Director of the Heart Transplant Service at Baylor College of Medicine.

He was recruited to MD Anderson Cancer Center to establish a cardiomyopathy program and a fully integrated interventional cardiology program. He was the first to establish a cardiomyopathy service within a cancer hospital and was able to establish standards for cardioprotection prior to Anthracycline based therapies and investigate novel mechanisms which lead to recovery of cardiac function in chemotherapy induced cardiomyopathy from Anthracyclines, Tyrosine Kinase Inhibitors and radiation induced cardiomyopathy.

Dr. Durand developed the largest DNA/Tissue bank of Chemotherapy induced Cardiomyopathy to detect polymorphisms to predict risk of development of heart failure. He has developed the first cardiac device clinic at MD Anderson utilizing mobile device monitoring of patients with arrhythmias’ and heart failure. He has over 100 publications in peer reviewed journals.

He serves as an IRB Co-chair and is a national and international speaker for cardioncology, he was recently appointed to the American Heart Association New Cardioncology Council and serves as Co-PI on several clinical trials for Stem Cell Therapy for Anthracycline- induced Cardiomyopathy.

Primary Appointment

Professor, Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Texas A& M University, Houston, Texas

Adjunct Clinical Assistant Professor, Methodist DeBakey Heart Center, Houston, Texas

Adjunct Clinical Assistant Professor, Baylor College of Medicine, Houston, Texas

Research Interests

My major research is dedicated to understanding the molecular genetics of cardiomyopathies, primarily the identification of genes responsible for cardiomyopathy of all etiologies. My work also focuses on defining the molecular mechanisms involved in chemotherapy-induced cardiomyopathy. Limited studies have been conducted to define the genetic basis of why patients undergoing cancer treatment develop heart failure and respond to standard medical therapy for treatment of heart failure. I have established the world’s largest database of DNA from patients with heart failure secondary to chemotherapy and have future plans to perform genotyping to identify heart failure susceptibility genes which may predispose patients to development of left ventricular dysfunction and potentially response and recovery of cardiac function. To this date we now have over 600 samples and have plans on obtaining 3000 samples. In addition, I have also developed a tissue bank for further expression studies to identify critical pathways which are common to cancer biology and cardiovascular biology.

I was the first to establish a cardiomyopathy service within a cancer hospital and was able to establish standards for cardioprotection prior to Anthracycline based therapies and investigate novel mechanisms which lead to recovery of cardiac function in chemotherapy induced cardiomyopathy from Anthracyclines, Tyrosine Kinase Inhibitors and radiation

I developed the first cardiac device clinic at MD Anderson utilizing mobile device monitoring of patients with arrhythmias’ and heart failure. I have over 100 publications in peer reviewed journals.

My areas of scientific interests also includes genotyping single nucleotide polymorphisms of Tyrosine Kinase Inhibitor-related cardiomyopathy, and acute coronary syndromes in cancer patients with Thrombocytopenia

I serve as an IRB Co-chair and is a national and international speaker for cardioncology, I was recently appointed to the American Heart Association New Cardioncology Council and serves as Co-PI on several clinical trials for Stem Cell Therapy for Anthracycline- induced Cardiomyopathy.

Education & Training

Degree-Granting Education

1988	Medical College of Wisconsin, Milwaukee, Wisconsin, US, MD
1984	California State University, Long Beach, California, US, BS in Physiology and Chemistry

Postgraduate Training

2021-2021	Life/Career Coach, Life Coach, Rice University-Doerr Institute for New Leaders, Houston, Texas
2020-2020	Coach Rice-Leadership Coaching Program, Leadership Coaching Program, Jesse H. Jones Graduate School of Management, Houston
2016-2016	Harvard Manage Mentor Pilot Program, Leadership, MD Anderson Cancer Center, Houston, Texas
2016-2016	Heart of Leadership, Leadership, MD Anderson Cancer Center, Houston, Texas
2009-2010	Certification, Genetic Epidemiology, Washington University School of Medicine, St. Louis, Missouri
2008-2012	Executive Development Certificate, Management and Leadership, MIT Sloan School of Management, Cambridge, Massachusetts
2007-2007	Executive Development Program, Technology and Entrepreneurship Workshop, Rice University, Houston, Texas
2006-2006	Clinical Safety Effectiveness Training Program, Quality Improvement and Patient Safety, MD Anderson Cancer Center, Houston, Texas
2006-2007	Faculty Leadership Academy, Leadership, MD Anderson Cancer Center, Houston
2006-2006	Executive Program, Faculty Leadership, The University of Texas MD Anderson Cancer Center, Houston, Texas
2006-2006	Executive Training, Clinical Safety and Effectiveness, Training Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
2005-2005	Executive Development Program, Physicians in Management, American College of Physician Executives, Tucson, Arizona
2004-2004	Executive Development Program, Negotiation Strategies, Kellogg School of Management, Evanston, Illinois
2004-2004	Executive Development Program, Technology and Entrepreneurship Workshop, Rice University, Houston, Texas
2003-2003	Executive Development Program, Executive Development Program, Wharton Business School, Philadelphia, Pennsylvania
2002-2002	Executive Development Program, Leadership, Harvard Medical School, Boston, Massachusetts
1996-1998	Research Fellowship, Cardiovascular Molecular Biology/Genetics, Baylor College of Medicine, Houston, Texas
1995-1997	Clinical Fellowship, Cardiology, Baylor College of Medicine, Houston, Texas
1995-1995	Externship, Genetics, Columbia University, New York, New York
1994-2004	Certified Instructor, Advanced Cardiac Life Support, Cardiology, Methodist Hospital, Houston, Texas
1992-1996	SCOR Fellow, Specialized Center of Research, Cardiovascular Molecular Biology, Baylor College of Medicine, Houston, Texas
1992-1996	Research Fellowship, Baylor College of Medicine, Houston, Texas
1992-1994	Research Fellowship, Cardiovascular Molecular Biology, Baylor College of Medicine, Houston, Texas
1990-1991	Post-doctoral Fellow, Cardiovascular Basic Research, Loyola University Medical Center, Maywood, Illinois
1988-1992	Clinical Residency, Internal Medicine, Loyola University Medical Center, Maywood, Illinois

Licenses & Certifications

2025	Certified Life Coach
2018	Drug Enforcement Administration
2006	American Board of Internal Medicine, Cardiovascular Disease
1997	Medical

Experience & Service

Faculty Academic Appointments

Adjunct Assistant Professor, The University of Texas Health Science Center at Houston, Houston, Texas, 2021 - 2022

Associate Professor, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2010 - 2017

Assistant Professor, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2000 - 2010

Administrative Appointments/Responsibilities

Quality Officer, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2007 - 2018

Other Professional Positions

Associate Reviewer, Heath Research Council of New Zealand, 2011 - 2012

Cardiovascular Consultant, Cardiology, St Jude Children's Research Hospital, Memphis, TN, 2007 - Present

Consultant, Revolution Health, Houston, TX, 2007 - 2008

Extramural Institutional Committee Activities

Co-Chair, Pulmonary Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Med Tech Innovation Council, MD Anderson Cancer Center, 2024 - Present

Member, MDACC Innovations committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

Committee Member, Outstanding Clinical Service Award in Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, 2019 - Present

Committee Member, American Heart Association, The University of Texas MD Anderson Cancer Center, 2019 - Present

Co-Chair, Cardiology Effectiveness Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Clinical Ethics Consultation Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020

Mentor, American Society of Clinical Oncology Diversity, The University of Texas MD Anderson Cancer Center, 2017 - 2018

Co-Chair, Search Committee for Chair, Department of Health Care Disparities Research, The University of Texas MD Anderson Cancer Center, 2015 - Present

Associate, Clinical Alarm Safety Multidisciplinary Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

Associate, Search Committee Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Member, Division Head Radiation Oncology Search Committee, The University of Texas MD Anderson Cancer Center, 2014 - 2015

Associate, EPIC Executive Core Committee, The University of Texas MD Anderson Cancer Center, 2013 - Present

Chair, Anti-Bullying Task Force, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Associate, Clinical Effort Standardization and Faculty Incentive Program Committee, The University of Texas MD Anderson Cancer Center, 2013 - 2014

Associate, Faculty Health Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Associate, Institutional Faculty Advisory Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2014

Associate Editor, Editorial Board Sentinel, The University of Texas MD Anderson Cancer Center, 2012 - 2013

Chair, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2012 - 2013

Chair, Multidisciplinary Cardiac Tumor Board, The University of Texas MD Anderson Cancer Center, 2012 - Present

Associate, Women's Faculty Programs Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2015

Associate, CME Advisory Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2014

Associate, Facilities Steering, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Associate, PRS Executive Council, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Chair, Graduate Medical Education, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Chair Elect, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Executive Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2011 - 2013

Member, Electronic Health Record Incentive Program Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Chairman, Subcommittee-Expense Analysis of Therapeutics, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Associate, Clinical Operations Subcommittee, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Member, Women's Faculty Advisory Committee, The University of Texas MD Anderson Cancer Center, 2011 - 2012

Judge, Trainee Research Day-Cancer Survivorship, The University of Texas MD Anderson Cancer Center, 2011

Member, Faculty Health Advisory Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present

Chair, Faculty Welfare Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2016

Associate, Search Committee Chairman Department of Emergency, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Associate, Chemistry Director Search Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Chair, Mid-Term Review Committee for Assistant Professor Promotion to Associate Professor, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Co-Chair, Faculty Welfare Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Associate, Quality Council, The University of Texas MD Anderson Cancer Center, 2010 - 2017

Member, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, 2010 - 2015

Chair Elect, Executive Committee of Faculty Senate, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Chair, Mid-Term Review Committee for Assistant Professor Promotion to Associate Professor, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Panel Member, Chemistry Director Faculty Search Committee, The University of Texas MD Anderson Cancer Center, 2010

Judge, Cancer Survivorship, The University of Texas MD Anderson Cancer Center, 2010

Panel Member, Search Committee Chairman Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 2010

Member, Quality Council-Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 2010

Member, Advisory Committee, Baylor College of Medicine, 2009 - Present

Vice-Chair Elect, Graduate Medical Education Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2011

Judge/Reviewer, Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2009

Member, American Heart Association Board of Directors, The University of Texas MD Anderson Cancer Center, 2008 - Present

Chairman, Cardiology Department Search Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2009

Judge/Reviewer, Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2008

Chairman, Graduate Medical Education Budget Subcommittee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Physician Scientist Search Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2008

Consultant, Investigation of cardiovascular events in chemoprevention clinical trials with Cox-2 Inhibitors, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2005 - Present

Consultant for investigation of cardiovascular events in chemoprevention clinical trials with Vitamin E, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2005 - Present

Member, Conquest Advisory Board, The University of Texas MD Anderson Cancer Center, 2004 - Present

Council Member, Research Administration Scientific Advisory Council, The University of Texas MD Anderson Cancer Center, 2004 - Present

Committee Member, Interventional Cardiology Committee, The University of Texas MD Anderson Cancer Center, 2003 - Present

Leader, Heart Success Task Force, The University of Texas MD Anderson Cancer Center, 2003 - Present

Committee Member, Faculty Achievement Awards Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2006

Committee Member, Anesthesia Chairman Search Committee, The University of Texas MD Anderson Cancer Center, 2003 - 2004

Council Member, Executive Council- Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2002 - Present

Founder, Heart to Heart Support Group, The University of Texas MD Anderson Cancer Center, 2002 - Present

Committee Member, Faculty Senate Committee, The University of Texas MD Anderson Cancer Center, 2002 - 2006

Co-Chair, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2001 - Present

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2001 - Present

Committee Member, CME Advisory Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2006

Committee Member, Sedation Committee, The University of Texas MD Anderson Cancer Center, 2001 - 2006

Member, Executive Committee - AHA, American Heart Association, 2000 - Present

Founder, Heart Success Cardiomyopathy Program, The University of Texas MD Anderson Cancer Center, 2000 - Present

Member, Multi-Organ Transplant Center Committee, The Methodist Hospital, 1997 - 2001

Member, Infection Prevention and Control COmmittee, The Methodist Hospital, 1991 - 2001

Editorial Activities

Editorial Board, Frontier Journal, 2024 - Present

Section Editor-Cancer, Texas Heart Institute Editorial Board, 2021 - Present

Editorial board, Journal of Cardio-Oncology, 2015 - Present

Editorial Board, Congestive Heart Failure, 2006 - Present

Guest Editor, Cardiology Research and Practice, 2004 - 2005

Honors & Awards

2020 - 2021	Superdoctors -Cardiology/Heart Failure
2017	Department of Internal Medicine, Division of Cardiovascular Diseases MD Anderson Cancer Center Faculty of the Year
2017	Inaugural Fellow Heart Failure Society of American
2016	Fellow American Heart Association
2016	Inaugural Fellow Heart Failure Society of America
2016	Faculty Clinical Excellence Award-Nominee, MD Anderson Cancer Center, Division of Internal Medicine
2015 - 2023	Distinguish Alumni Award, California State University Long Beach
2013	Best Teacher Award, University of Texas MD Anderson Cancer Center, Cardiology Fellows
2012	Judge 24th Annual Young Inventor’s Showcase
2011	Houston’s Top Doctors
2010	Houston's Top Doctors, Houston Magazine
2008	Who’s Who in America
2007	American College of Cardiology
2007	Americas Top Cardiologist
2007	American College of Physicians
2006	American College of Chest Physicians
2005	Young Investigators Award, MD Anderson Cancer Center
2005	MD Anderson Cancer Center Young Investigators Symposium Top Ten Research Award, MD Anderson Cancer Center
2002	Top Ten Research Award, MD Anderson Young Investigator’s Symposium
2002	MD Anderson Cancer Center Young Investigators Symposium Top Ten Research Award, MD Anderson Cancer Center
1996	Finalist Young Investigators Award First Runner Up, American College of Cardiology
1996	First Place- Basic Research Division, Baylor College of Medicine- Department of Medicine
1992 - 1993	Marion Merrill Dow Award in Molecular Cardiology, Marion Merrill
1988	Peer Counselor, Medical College of Wisconsin
1986 - 1987	Chairman Academic Affairs Committee, Medical College of Wisconsin,
1985	Student Representative Admissions Committee, Medical College of Wisconsin
1984	Student Representative Academic Affairs, Medical College of Wisconsin
1984	President Mortar Board National Honor Society, California State University Long Beach
1984	UCLA Pavilion- Host, Los Angeles Olympic Organizing Committee
1980	Outstanding Student Award, California State University Long Beach
1980	Outstanding Scholar Award, California State University Long Beach
1978	First Place National French Competition Level 1A

Professional Memberships

Heart Failure Society of America

2016 - Present

European Association of Physician Health

2010 - Present

Canada Foundation for Innovation

2009 - Present

American Association of University Professors

2007 - Present

American College of Chest Physicians

2007 - Present

American College of Physicians

2007 - Present

American College of Cardiology

2007 - Present

Cardiology Safety Research Consortium

2006 - Present

International Cardioncology Society

2006 - Present

American College of Physician Executives

2004 - Present

American Society of Echocardiography

2004 - Present

American Society of Clinical Oncology

2003 - Present

Houston Heart Failure Society

2002 - Present

Harris County Medical Society

2001 - Present

Public Responsibility in Medicine and Research

2001 - Present

American College of Physician Executives

2001 - Present

Harris County Medical Society

2000 - Present

Society for Cardiac Angiography and Interventions

2000 - Present

Texas Medical Foundation

2000 - Present

Heart Failure Society of America

1997 - Present

American College of Cardiology

1995 - Present

Texas Genetics Society

1992 - Present

Association American College of Physicians

1992 - Present

American Heart Association

1992 - Present

Selected Presentations & Talks

Local Presentations

2025. Echocardiogram-Based Screening for Pulmonary Hypertension in Patients with Cancer. Poster. MD Anderson DoIM Research Retreat 2025. Houston, Texas, US.
2025. Amyloidosis, Multimodality Imaging and Endomyocardial Biopsy. Invited. MD Anderson Cancer Center Cardiology Core Series. Houston, Texas, US.
2025. Financial Health for your Future. Invited. MD Anderson Core Oncology Series. Houston, Texas, US.
2025. Retirement and preparing for your Retirement. Invited. MD Anderson Cancer Center Senior Faculty Committee. Houston, Texas, US.
2025. Chemotherapy and Cardiotoxicity. Invited. MD Anderson APP Grand Grounds. Houston, Texas, US.
2025. Financial Literacy and Your Financial Future. Invited. MD Anderson Summer Externship Program. Houston, Texas, US.
2025. Management of Immunotherapy Associated Cardiomyopathy. Invited. 3rd Virtual World Symposium in Oncologic Critical Care. Houston, Texas, US.
2024. Financial Bootcamp for MD Anderson Cancer Center Faculty. Invited. Financial Planning, Stocks, Bonds, and Retirement Planning. Houston, Texas, US.
2024. Cardiac Risk in AL Amyloidosis Patients Amidst Advances in the Current Era. Invited. Bradley Z. Naifeh Amyloidosis Conference. Houston, Texas, US.
2024. Novel Agents in Cancer Therapies and Cardiomyopathy. Houston, Texas, US.
2024. Financial Literacy. Invited. Fellows MD Anderson Cancer Center. Houston, Texas, US.
2024. What Should I Know About Diagnosis and Treatment. APP Grand Rounds. Houston, Texas, US.
2024. Faculty Financial Competency Series. Invited. MD Anderson Faculty. Houston, Texas, US.
2024. AL Amyloid Cardiomyopathy. Invited. Methodist Hospital Amyloidosis Conference. Houston, Texas, US.
2021. Recovery of Chemotherapy Related Cardiac Injury. Enjoy Science Webinar Series. Houston, Texas, US.
2021. California State University Long Beach Commencement 2021 - Can Failure Be Your Success. California State University Long Beach Commencement 2021. Anaheim, CA, US.
2021. Financial Bootcamp. Financial Planning, Stocks, Bonds, and Retirement Planning. Houston, Texas, US.
2021. Molecular Studies of Anthracycline Cardiomyopathy. Institutional Science Seminars Enjoy Science Series. Houston, Texas, US.
2021. Financial Literacy in Early Career Development. American College of Cardiology - Iowa Chapter. Washington, DC, US.
2021. Galectin 3 Levels in Cardioncology. Department Clinical Rounds. Houston, Texas, US.
2021. Contract Negotiations. The University of Texas MD Anderson Cancer Center Pathology Fellows. Houston, Texas, US.
2021. Cardiac Contractility Modulation in Anthracycline Cardiomyopathy. MD Anderson Cancer Center Faculty Conference. Houston, Texas, US.
2021. Being the CEO of Your Professional and Financial FUture. Pathology Fellows. Houston, Texas, US.
2019. Cardiac Biopsy and Pathological Findings for Myocarditis with Checkpoint Inhibitors. IOTox Clinical Trial. Houston, Texas, US.
2019. Financial Bootcamp for Pathology Fellows. Houston, Texas, US.
2019. Treatment of CLL and Cardiotoxicity. Society of Hematology and Oncology. Houston, Texas, US.
2019. Financial Literacy for Residents and Fellows. Houston, Texas, US.
2017. Arrhythmia Induced Cardiomyopathy. Texas Heart Institute Symposium on Cardiovascular Regenerative Medicine. Houston, Texas, US.
2014. Heart Disease in the Cancer Patient , Partners in Knowledge. News in Cancer Lecture. Houston, Texas, US.
2013. Secondary Prevention of Chemotherapy Induced Cardiotoxicity. Kreg Anderson Workshop: Prevention of Chemotherapy Induced Cardiotoxicity. Houston, Texas, US.
2013. Cardiac Issues in Cancer Survivors, Advances in Cancer Survivorship Practice. Houston, Texas, US.
2013. Evaluation, Treatment, and Survival of Cardiac Amyloid. Cardiology Grand Rounds. Houston, Texas, US.
2013. The Perioperative Fluid Management of Patients with Pre-Existing Cardiac Conditions. Gynecology Oncology Fellowship Conference. Houston, Texas, US.
2013. Cardiac Issues in Cancer Survivors. Advances in Cancer Survivorship Practice , A conference for Healthcare Professionals. Houston, Texas, US.
2013. Practical Approaches to Management and Treatment of Chemotherapy - Induced Cardiomyopathy. Texas Heart Institute/St Luke's Hospital/Baylor College of Medicine Fellows Conference. Houston, Texas, US.
2013. Complexz Cardiovascular Complications of Cancer Therapies. The Methodist Hospital/DeBakey Cardiovascular Institute. Houston, Texas, US.
2013. Managing Cardiotoxicity in Breast Cancer Patients Treated with FAC. Breast Medical Oncology. Houston, Texas, US.
2012. Molecular Biology in Clinical Diagnosis. Houston, Texas, US.
2012. The Final Common Pathway of Cardiology and Oncology. Updates in Cardiology. Houston, Texas, US.
2012. The Andrenergic System: The Final Common Pathway of Cardiology and Oncology. Updates in Cardiology. Houston, Texas, US.
2011. Cardiomyopathy, Cardio Board Review Sessions. Cardio Board Review Sessions. Houston, Texas, US.
2011. Emerging New Therapies for Heart Disease and Cancer. Survivorship Conference for Physicians and Health Care Professionals. Houston, Texas, US.
2011. Indications for LVAD in the Cancer Patient. Updates in Cardiology. Houston, Texas, US.
2011. Heart Disease and Cancer. PIKNIC. Houston, Texas, US.
2011. Heart Disease and Cancer. PIKNIC - Bay Area. Houston, Texas, US.
2011. Hemochromatosis: Diagnosis and Management. Updates in Cardiology. Houston, Texas, US.
2011. Cardiac Issues in Cancer Survivorship. Survivorship Conference. Houston, Texas, US.
2011. Selective Targeted Therapy and Heart Rate Reduction. Updates in Cardiology. Houston, Texas, US.
2011. Amyloidosis and Cardiac Disease. Clinical Pathology Conference. Houston, Texas, US.
2011. Navigating Cancer and Heart Disease. Clear Lake, Texas, US.
2011. Cardiotoxicity and the Cancer Patient. Cardiology Fellows Lecture Series. Houston, Texas, US.
2010. Cardiac Complications of Cancer Therapy. GME Core Curriculum Lectures. Houston, Texas, US.
2010. Cardiac Complications of Cancer Therapy. GME Core Curriculum Series. Houston, Texas, US.
2010. Management of Heart Failure. 7th Annual Cardiology Board Review Lecture Series. Houston, Texas, US.
2010. Toxic Cardiomyopathy-Chemotherapy. Cardiology Core Lecture Series. Houston, Texas, US.
2010. Assessment of LV Function. Updates in Cardiology. Houston, Texas, US.
2010. Management of High Risk Hypertension Patients. Cardiac Cath Lab Inservice. Houston, Texas, US.
2010. Treatment of Hypertension in High Risk Patients?. Cardiology Cath Lab InService. Houston, Texas, US.
2010. The PreChemo Evaluation of Phase One Studies: Biomarkers and Cardiac Imaging. Clinical Trials Faculty Meeting. Houston, Texas, US.
2010. Chemotherapy and Cardiotoxicity. The University of Texas MD Anderson Cancer Center, Radiation Oncology. Nassau Bay, TX, US.
2010. Molecular Biology in Clinical Diagnosis. 2010 SMART Program Seminar Series. Houston, Texas, US.
2010. Effects of Avastin-like Meds. Graduate Education and Training Quarterly Meeting. Houston, Texas, US.
2010. Heart Disease and Cancer. PIKNIC - MD Anderson Cancer Center Place of Wellness. Houston, Texas, US.
2010. Prevention and Treatment of Patients with Cancer and Cardiovascular Disease. Preventive Cardiology Forum. Houston, Texas, US.
2010. Cardiotoxicity and Cancer Therapies. Cardiology Fellowship Program Didactic Series. Houston, Texas, US.
2010. Medical and Surgical Approaches to Cancer Patient with Cardiotoxicity. Houston, Texas, US.
2010. Cardiotoxity and Cancer Therapies. The University of Texas MD Anderson Residency Graduate Medical Education Series. Houston, Texas, US.
2010. Prevention and Management of Cardiotoxicity in Cancer Patients. THI Cardiology Fellowship Educational Conference. Houston, Texas, US.
2010. Understanding Cancer and Heart Disease. The University of Texas MD Anderson Cancer Center Place of Wellness. Houston, Texas, US.
2009. Clinical Diagnosis with Molecular Biology. SMART Program Lecture Series. Houston, Texas, US.
2009. Cancer and Heart Disease. The University of Texas MD Anderson Cancer Center, Lymphoma. Houston, Texas, US.
2009. Treatment and Prevention of Cardiotoxicity in Cancer Patients. Graduate Medical Education COre Curriculum. Houston, Texas, US.
2009. Smoking and Heart Disease. Texas Wellness Smoking Policy Symposium. Houston, Texas, US.
2008. Living Fully with and Beyond Cancer. Anderson Network Patient and Caregiver Conference. Houston, Texas, US.
2008. Treatment of Atrial Fibrillation in the ICU. Critical Care Lecture Series. Houston, Texas, US.
2007. Thrombosis in the Cancer Patient. Advanced Practice Meeting. Houston, Texas, US.
2007. Survivorship and Cardiotoxicity. 19th Annual Patient and Caregiver Conference. Houston, Texas, US.
2007. Cardiac Complications in the Cancer Patient: Heart Success. 2nd Annual Oncology Nursing Symposium. Houston, Texas, US.
2007. Tyrosine Kinase Inhibitors : Clinical Manifestations. Houston, Texas, US.
2007. thrombosis in the Cancer Patient : There is not Safety in Numbers. Cardiology & Oncology Partnership: Bridging the Gaps to Improve Patient Outcomes. Houston, Texas, US.
2007. Molecular Biology in Clinical Diagnosis. Baylor College of Medicine SMART Program. Houston, Texas, US.
2007. Reversibility of Chemotherapy - Induced Heart Failure. Cardiac Transplant Lectures. Houston, Texas, US.
2007. Cardiotoxicity in ederly Patients with NHL. CCOP Webcast. Houston, Texas, US.
2007. Cardiotoxicity in the Pediatric Cancer Patient. Pediatric Tumor Board Conference. Houston, Texas, US.
2007. Cardiac Toxicity in Chemotherapy. Gynecologic Oncology Conference. Houston, Texas, US.
2006. Cardiology Issues in Cancer Care. Research Base Annual Investigators Meeting. Houston, Texas, US.
2006. Prevention of Heart Failure in Adults. Preventative Cardiology Forum XVI. Houston, Texas, US.
2006. Treatment of Cardiac Complications in the Cancer Patient. Houston Heart Failure Society. Houston, Texas, US.
2006. Molecular Biology of Dilated Cardiomyopathy. Baylor College of Medicine SMART Program. Houston, Texas, US.
2006. Cardiomyopathy and Anesthetic Considerations. Current Trends in Cardiothoracic Anesthesia. Houston, Texas, US.
2006. Cancer and Heart Disease: Failure in Not an Option. Partners in KNowledge, News in Center. Houston, Texas, US.
2006. Biomarkers and Heart Disease. Post Graduation Association Journal Club. Houston, Texas, US.
2006. Cardiovascular Complications in the Cancer Patient. Houston Nursing Society. Houston, Texas, US.
2005. Update on Congestive Heart Failure. Houston, Texas, US.
2005. Mechanisms of Cardiotoxic Therapy in Cancer Patients. Houston, Texas, US.
2005. Molecular Biology in Clinical DIagnosis. Houston, Texas, US.
2005. From Heart Failure to Heart Success: Development of the Heart Failure Program at MD Anderson Cancer Center, A Feasibility Study. Houston, Texas, US.
2005. Cardiovascular Complications in Cancer Patients: An Evidence Based Approach. Houston, Texas, US.
2005. Cardiovascular Complications in Cancer Patients: An Evidence Based Approach. Houston, Texas, US.
2004. Genes, Polymorphisms and Heart Disease in the Cancer Patient; A Model for the Future. Houston, Texas, US.
2004. Cardiac Challenges in the Cancer Patient : What you need to know. Houston, Texas, US.
2004. Genes and Cardiomyopathy: Failure is not an Option. Houston, Texas, US.
2004. Intra-Operative Transesophageal Echocardiography Workshop Cardiomyopathy : Etiology and Treatment. Houston, Texas, US.
2004. Myocardial Diseases; Genetics. Texas Medical Center Board Review. Houston, Texas, US.
2001. Breakfast with the Experts, Management of Congestive Heart Failure. Breakfast with the Experts GSK. Houston, Texas, US.
2001. What's new in CHF?. ANnual Southwest Percutaneous Vascular Meeting. Houston, Texas, US.

Regional Presentations

2024. Financial Success In Early Faculty Development. Invited. San Antonio Pathology Coference. San Antonio, TX, US.
2021. Funding Your Life and Profession. American College of Cardiology - Local Chapter Connecticut - Yale University Faculty, US.
2021. Current Paradigms in Cardioncology of the Cancer Patient Survivor Cancer Therapeutic Agents of Arrhythmia Targeted Treatment based on Possible Mechanisms. Rush University Second Biennial. Chicago, IL, US.
2021. Challenging Cases in Cardio-Oncology. American College of Cardiology Scientific Meetings. Washington, DC, US.
2018. Cardioncology: The Role of the Cardiologist in the Modern Oncologic Care. Scripps Cardiovascular Institute Grand Rounds. La Jolla, CA, US.
2018. New Technologies of Therapeutics and Cardiovascular Imaging for Oncocardiology. Oncology Grand Rounds. Houston, TX, US.
2015. New Innovations and Technologies in Management of Anthracycline Induced Cardiomyopathies. Pediatric Grand Rounds. Houston, TX, US.
2015. Onco-Cardiology: Developing a New Medical Subspecialty at Your Institution. Houston Methodist DeBakey Heart and Vascular Center Grand Rounds. Houston, TX, US.
2013. Medical Business Bootcamp for Fellows. American College of Cardiology - Texas Chapter Annual Meeting. San Antonio, TX, US.
2013. Tyrosine Kinase Inhibitors Related Toxicity. Advances in Oncology Institutional Grand Rounds. Houston, TX, US.
2013. Amyloids: Diagnosis, Management and Treatment. Cardiology Grand Rounds. Houston, TX, US.
2012. Successful Careers in Health Science are a Journey, not a Destination. Houston Premedical Academy (HPA) Research Symposium. Houston, TX, US.
2011. Update in Cancer and Cardiomyopathy. Methodist DeBakey Heart & Vascular Center Grand Rounds. Houston, TX, US.
2011. Management of Heart Failure : CMS Core Measures. Internal Medicine and Cancer Survivorship Grand Rounds. Houston, TX, US.
2011. Targeted Cancer Therapies and Cardiotoxicity. Cardiology Grand Rounds. Houston, TX, US.
2011. Prevention and Detection of Cardiotoxicity in Melanoma Patients. Melanoma Grand Rounds. Houston, TX, US.
2010. Cardiomyopathy, Infectious Disease, & Thyoma. Internal Medicine and Cancer Survivorship Grand Rounds. Houston, TX, US.
2010. New Pathways for Development of Cancer Related Cardiotoxicities. Winter Conference for Heart Failure Research. Houston, TX, US.
2010. Cardiovascular Specialty of Next Decade: Bridging Cardiology and Oncology a New Specialty Arises. Texas Heart Institute Cardiology Grand Rounds. Houston, TX, US.
2010. Cardiovascular Specialty of Next Decade: Bridging Cardiology and Oncology a New Specialty Arises. St. Luke's Cardiology Grand Rounds. Houston, TX, US.
2010. Quality Improvement - Taking a Look at Ourselves. Cardiology Grand Rounds. Houston, TX, US.
2010. Current Perioperative Management of Patients with Coronary Artery Stents. Anesthesia/Surgical Grand Rounds. Houston, TX, US.
2009. Withdrawal of Cardiovascular Medications: A Tine to Evaluate Our Practice. Grand Rounds. Houston, TX, US.
2009. Cardiac Imaging in Cancer Patients: Looking into the Past to see the Future. Institutional Grand Rounds. Houston, TX, US.
2007. Atrial Fibrillation. Division of Internal Medicine Grand Rounds. Houston, TX, US.
2007. Cancer and Hypertension. Nephrology Grand Rounds. Houston, TX, US.
2007. Anti-Angiogenesis Factors and Heart Disease: Highlights of the Heart Failure Society of America Scientific Sessions. Cardiology Grand Rounds. Houston, TX, US.
2007. Acute Coronary Syndromes and the Cancer Patient. Tumor Conference. Corpus Christi, TX, US.
2007. Thrombosis in the Cancer Patient. Advanced Nurse Practitioner Grand Rounds. Houston, TX, US.
2007. Vascular Endothelial Growth Factors and Heart Failure. Internal Medicine Grand Rounds. Temple, TX, US.
2007. Cardiovascular Complications with Cancer Therapies - The Vulnerable Patient. Methodist Hospital Grand Rounds. Houston, TX, US.
2007. Cardiotoxicity: Clinical Manifestations of Tyrosine Kinase Inhibators. Grand Rounds, University of Texas MD Anderson Cancer Center, Division of Internal Medicine/Division of Cancer Medicine. Houston, TX, US.
2007. Anti-Angiogenesis Factors and Heart Failure. Cardiology Grand Rounds. Houston, TX, US.
2006. Management of Congestive Heart Failure. University of Texas Medical School Grand Rounds. Houston, TX, US.
2006. Management of Acute Coronary Syndromes in the Cancer Patient, Time for Quality Improvement. Division of Internal Medicine Grand Rounds. Houston, TX, US.
2005. Current Guidelines in Heart Failure Management: Ethnicity and Disease. University of Texas Health Science Center Grand Rounds. San Antonio, TX, US.
2005. Cancer and Heart Disease. Grand Rounds. Houston, TX, US.
2005. Antiplatelet Therapy and Cardiac Stents: Implications for Chemotherapy. Grand Rounds. Houston, TX, US.
2004. Heart Failure and Cancer: New Treatment Strategies. Grand Rounds. Houston, TX, US.
2004. Acute Coronary Syndromes and Thrombocytopenia in the Cancer. University of Texas Medical School Grand Rounds. Houston, TX, US.
2002. Altering the Course of Congestive Heart Failure. American Academy of Family Physicians. Sanb Antonio, TX, US.
2002. Current Trials in Congestive Heart Failure. Congestive Heart Failure Symposium. Houston, TX, US.
2002. What's New in CHF?. Annual Southwest Percutaneous Vascular Meeting. Houston, TX, US.
2002. Chemotherapy-Induced Heart Failure. Congestive Heart Failure Symposium. San Antonio, TX, US.
2000. Beta Blockers as a Bridge to the DeBakey Left Ventricular Assist Device. Galveston, TX, US.
1999. Beta Blockers in the Treatment of Heart Failure. Texas Tech Grand Rounds. Amarillo, TX, US.
1999. Beta Blockers in the Treatment of Heart Failure. Amarillo, TX, US.
Multimodality Imaging in Cardioncology ; How to Use in Your Practice. Winter Symposium, US.

National Presentations

2025. Drug Development in Oncology and Off Target Cardiac Effects. Invited. Pharma R&D 7th International Conference on Pharm Science Research & Development. San Francisco, CA, US.
2025. How Anticancer Therapies Interact with the Heart?. Invited. 2025 Drug R&D. Salt Lake City, UT, US.
2025. Chemotherapy Associated Cardiotoxicity and Drug Development. Invited. 7th International Conference Pharm science Research and Development. Boston, Massachusetts, US.
2024. Chemotherapy Associated Cardiotoxicity and Drug Development Storm Chaser of Cleaner?. Invited. VI International Conference on PharmScience Research & Development. Boston, MA, US.
2024. Inherited cardiomyopathies, genetic predisposition and myocardial recovery. Invited. Utah Cardiac Recovery Symposium (U-CARS). Salt Lake City, UT, US.
2024. Recovery of Heart Function in Inherited Cardiomyopathies. Invited. UCARS 2024. Salt Lake City, UT, US.
2024. Cardiotoxicity in Oncology Therapies. Invited. Pharma Drug Development Conference. Boston, MA, US.
2021. Financial Planning, American College of Cardiology, Iowa Chapter, Iowa City, IA, 3/6/2021. American College of Cardiology, Iowa Chapter. Iowa City, IA, US.
2021. Finding the Big Ideas. Bench to Bedside Conference Series: Cancer and Cardiovascular Disease. Washington, DC, US.
2021. Sessions: Starting Your Cardioncology Practice 101. Heart Failure Society of America. Houston, TX, US.
2021. Top Early Career Tips in Cardio-Oncology Paving the Way How to Train in Cardio-Oncology. American Heart Association - Scientific Sessions, US.
2020. The Intersection of Cardio-Oncology and Advanced HF: From Stage A to D. Heart Failure Society of America (HFSA). Rockville, MD, US.
2020. Developing and Growing Your Cardio-Oncology Practice: It Takes a Village. UPMC Heart and Vascular Institute. Pittsburgh, PA, US.
2019. Life with the Experts: Team Challenges in Prediction, Prevention and Treatment, Advancing the Cardiovascular Care of the Oncology Patient, American College of Cardiology, Washington, DC, 2019. American College of Cardiology. Washington, DC, US.
2019. . ACC Heart House, American College of Cardiology. Washington, DC, US.
2019. The Interprofessional Survivorship Care Team Collaborative Care to Achieve the Best Outcomes, Advancing the Cardiovascular Care of the Oncology Patient. American College of Cardiology. Washington, DC, US.
2019. Team Imaging Interpretation: Putting Your Rapid-Fire Skills to the Test, Advancing the Cardiovascular Care of the Oncology Patient, American College of Cardiology, Washington, DC, 2019. American College of Cardiology, Washington. Washington, DC, US.
2019. 1st Annual Cardioncology Conference. 1st Annual Cardioncology Conference. Pisstburg, PA, US.
2019. Team Challenges in Cardio-Oncology: A Case Based Approach to Bleeding, Thrombosis and Ischemic Disease, Advancing the Cardiovascular Care of the Oncology Patient, American College of Cardiology, Washington, DC, 2019. American College of Cardiology. Washington, DC, US.
2019. Cardiovascular Risk Alert in Heme Malignancies: Stem Cell Transplant and Cardiotoxic Exposures, American College of Cardiology, Washington, DC, 2019. American College of Cardiology. Washington, DC, US.
2018. Web Based Technologies to Identify Cardiotoxicities in Clinical Oncology Trials. New York, NY, US.
2017. Cardiomyopathy with Herceptin: When should you stop Herceptin, If Ever?, American College of Cardiology Scientific Sessions, Washington, DC, 3/2017. American College of Cardiology Scientific Sessions, Washington, DC, 3/2017. Washington, DC, US.
2017. Which Patient and Which Technique : An Imaging Debate What are the Strengths and Weaknesses of Suggested Modalities. Inaugural Meeting of the American College of Cardiology, US.
2017. Advancing Cardiovascular Care of the Oncology Patient. Inaugural Meeting of the American College of Cardiology, US.
2016. The Outcome of Pregnancy in Women with Chemotherapy Induced Cardiomyopathy. Fourth International Congress on Cardiac Problems in Pregnancy. Las Vegas, NV, US.
2015. Myocardial Biopsy for Anthracycline Toxicity: When , How and What For?. Heart Failure Society of America. San Diego, CA, US.
2015. Risk Stratification: How Do You Identify the High Risk Patient?. Scientific Sessions, American College of Cardiology. San Diego, CA, US.
2014. Therapy Related Cardiac Toxicity in Cancer Patients. Network of Oncologist and Researchers. Las Vegas, NV, US.
2014. The Cardioncology Clinic. Chicago, IL, US.
2013. Prevention of Chemotherapy-Induced Cardiotoxicity. Kreg Anderson Workshop. Houston, TX, US.
2013. Clinical Biomarkers in Cancer Treatment Related Cardiotoxicity: Detecting Asymptomatic Toxicity. National Cancer Institute/National Heart and Blood Institute. Bethesda, MD, US.
2012. Cancer and the Heart: Current Concepts, Global Conference on Perioperative Medicine: Care of the Elderly and the Cancer Patient. Global Conference on Perioperative Medicine. Houston, TX, US.
2012. Acute Cardiomyopathy in Cancer Patients. 2nd International Conference on Cancer and the Heart. HOUSTON, TX, US.
2012. Are we creating more stage A Heart Failure Patients with Chemotherapy?. American Heart Association Scientific Sessions, Los Angeles, CA, 11/2012. Los Angeles, CA, US.
2012. Treatment of Cancer Therapy Cardiomyopathy. 2nd International Conference on Cancer and the Heart. Houston, TX, US.
2012. Cancer, Cardiotxicity and Genetics. Scripps Cancer Center, 32nd Annual Oncology Nurses Symposium. San Diego, CA, US.
2012. Cardiotoxicity of Chemotherapy: Evaluation and Therapy, Heart Failure Society of America. 16th Annual Heart Failure Society of America Scientific Session. Seattle, WA, US.
2012. Emerging Diagnostic Treatment Options for Breast Cancer and Cardiotoxicity. National Consortium of Breast Center, 22nd Annual National Interdisciplinary Breast Center Conference. Las Vegas, NV, US.
2011. Case Presentation. Safety Research Consortium. Silver Spring, MD, US.
2011. Management of side effects in patients with advanced renal cell carcinoma. 10th International Kidney Cancer Symposium. Chicago, IL, US.
2011. Is Chemotherapy Creating a Stage B Population that Needs Treatment, Heart Failure Society of America, 15th Annual Heart Failure Society of America Scientific Sessions, Boston, MA, 9/2011. 15th Annual Heart Failure Society of America Scientific Sessions. Boston, MA, US.
2011. Clinical Features and Outcomes of Stress-Induced Cardiomyopathy in Cancer Patients, American College of Cardiology. New Orleans, LA, US.
2011. Cardiac Toxicity of Targeted Agents. , Network of Oncology Clinicians and Researchers. Las Vegas, NV, US.
2011. Successful Management of Cardiovascular Disease in the Cancer Patient: A Focus on Hypertension and Cardiomyopathy. Ocala, FL, US.
2011. Cancer and Cardiotoxicities. Wake-Med Cardiovascular Conference. Raleigh, NC, US.
2010. OncoCardiology: How to Manage Patients on Agents that Have Cardiovascular Effects (Cardiotoxicity and Delayed Side Effects. Oncology Clinical Trials, Oncology Research Symposium 2010. Oakland, CA, US.
2010. Cardioncology: What is the Future?. Vanderbilt Heart and Vascular Institute/IV Annual International Symposium. Nashville, TN, US.
2010. Toxicity Issues in the Management of RCC Patients. 9th International Kidney Cancer Symposium. Chicago, IL, US.
2010. Detecting Sub-clinical Treatment Induced Cardiac Toxicity: A New Paradigm. 2010 Fall Symposium ProMedica Cancer Institute. Toledo, OH, US.
2010. Journey of a Cardiologist - What's Your Specialty. National Youth Leadership Forum on Medicine. Houston, TX, US.
2010. Long Term Cardiac Effects of Cancer Therapies: New Approaches and Research. Harry E. Hynes CCOP Symposium. San Francisco, CA, US.
2010. Genome Wide Search for Adriamycin Cardiomyopathy. Summer Institute Program to Increase Diversity in Genetic Epidemiology. St Louis, MO, US.
2010. Tyrosine Kinase Inhibitors and Hypertension. Alaska Medical Center, Providence Cancer Center. Anchorage, AK, US.
2010. Anthracyclines and Trastuzumab Cardiotoxicity. Alaska Medical Center, Providence Cancer Center. Anchorage, AK, US.
2010. Cardiac Effects after Cancer Treatment: Opportunities for Survivorship Research. Southwest Oncology Group, Cancer Survivorship Committee. San Francisco, CA, US.
2009. Evidence of Beta Blockers Effectiveness in Management of Hypertension/Heart Failure. American Heart Association 22nd Annual Association of Black Cardiologist. Orlando, FL, US.
2009. Maximizing Cardiovascular Health after Breast Cancer Treatment,. 2009 Breast Cancer Symposium. San Francisco, CA, US.
2009. Managing Cardiovascular Toxicities in Renal Cell Carcinoma. Ninth International Congress on Genitourinary Malignancies. Washington, DC, US.
2009. Cardiovascular Complications with VEGF Inhibitors: Underlying Mechanism and Risk. 5th Annual Chicago Supportive Oncology Conference. Chicago, IL, US.
2008. High Mortality Rate are Associated with Withdrawal of Beta Blockers and Ace-Inhibitors in Chemotherapy-Induced Heart Failure. New Orleans, LA, US.
2008. Cardiovascular Complications with Vascular Endothelial Growth Factor Inhibitors: Underlying Biologic Mechanisms and Risk. ASCO Genitourinary Cancer Symposium. San Francisco, CA, US.
2008. Late Onset Heart Failure in HCT: Comorbid Conditions and Potential Impact on Survival. American Society of Clinical Oncology. Chicago, IL, US.
2007. Drug Induced Heart Disease. 11th Annual Heart Failure Society of America Scientific Sessions. Washington, DC, US.
2007. Heart Failure for the Consultant Cardiologist. American College of Cardiology 56th Annual Scientific Sessions. New Orleans, LA, US.
2007. Cardiovascular Management of Cancer Patients: Heart Failure in Cancer. American College of Cardiology 56th Annual Scientific Sessions. New Orleans, LA, US.
2007. Overview of Cardiovascular Complications with Cancer Therapy. American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, US.
2006. How to Prevent Cardiomyopathy after Cancer Treatment. Heart Failure Society of America 10th Annual Scientific Sessions. Seattle, WA, US.
2005. Cardiotoxicity in the Cancer Patient - Great Debates in Breast Cancer. Lake Tahoe, NV, US.
2005. What we are Learning from Clinical Trials: The Scope of the Problem. Heart Failure Society of America 9th Annual Sciedntific Sessions. Boca Raton, FL, US.
2002. Metabolic Syndrome: Understanding the Link to Cardiovascular Risk. Invited. Honolulu, HI, US.
1996. Localization of the Gene for Familial Dilated Cardiomyopathy. Invited. American College of Cardiology / Young Investigators Award. Orlando, Florida, US.
Cardioncology Programs in Hospital Networks, Is it really Necessary?, Aurora Health Grand Rounds, Aurora Health, Milwaukee,, WI. Aurora Health Grand Rounds, Aurora Health. Milwaukee, WI, US.
How to Mitigate Cardiotoxicity Stains and Proton Therapy for All- Childhood and Adult Cancer Patients and Survivors. Inaugural Meeting of American College of Cardiology. Washington, DC, US.

International Presentations

2019. Prevention of Cardiovascular Toxicities in Oncology Patients. Rosario, AR.
2019. Cardiotoxicity by Anthracyclines and AntiHer2. How to Estimate the Risk of Each Patient? Can Cardiotoxicity be Prevented?. International Cardio Oncology Society, AR.
2019. Case Studies in Cardioncology, National Congress of Cardiology. National Congress of Cardiology. Rosario, AR.
2019. Left Ventricular Dusfunction and heart Failure in Cardio-Oncology, Global Cardio-Oncology Summit, Sao Paulo, Brazil, 2019. Global Cardio-Oncology Summit. Sao Paulo, BR.
2019. Ace-Inhibitors and Beta Blockers as Cardioprotection with Breast Cancer Patients and Trastuzumab,Ace-Inhibitors and Beta Blockers as Cardioprotection with Breast Cancer Patients and Trastuzumab. Best of San Antonio Breast Cancer Symposium, Korean Society of Medical Oncology. Seoul, KR.
2019. Approach to the Treatment of Cardiotoxicity by Check Point Inhibitors. Association of Cardio-Oncology Society, AR.
2018. The Use of Echocardiography to Identify Cardiotoxicities. Seoul, KR.
2018. New Applicants for Treatment of Anthracycline Cardiomyopathy. THI International Symposium on Cardiovascular Regenerative Medicine. Houston, US.
2018. Can the Anthracyline njured Heart be Repaired. , US.
2018. Practice Based Evidence for Treatment of Pregnancy and Anthracycline Associated Cardiomyopathy, IT.
2017. The Use of Echocardiography to Identify Cardiotoxicities. 45th Annual Meeting of Korean Society of Echocardiography. Seoul, KR.
2017. Immunotherapy and Cardiovascular Toxic Effects, A.C. Camargo Cancer Center, Sao Paulo, Brazil, 4/2017. A.C. Camargo Cancer Center. Sao Paulo, BR.
2015. Acute Coronary Syndrome in Patients with Chemotherapy-Induced Thrombocytopenia, Tata Memorial Hospital, XIIIth Annual Conference on Evidence Based Management of Cancer in India, Mumbai, India, 2/2015. XIIIth Annual Conference on Evidence Based Management of Cancer in India. Mumbai, IN.
2015. Development of an Oncocardiology Program: The Future of Cancer. Delhi State Cancer Institute. New Delhi, IN.
2015. MRI as a Tool to Predict Chemotherapy-Induced Cardiotoxicity. XIIIth Annual Conference on Evidence Based Management of Cancer in India. Mumbai, IN.
2015. Risk Stratification and Monitoring for Anthracyclines. XIIIth Annual Conference on Evidence Based Management of Cancer in India. Mumbai,, IN.
2014. Preventative Strategies of Cardiotoxicity. Sírio-Libanês Teaching and Research Institute. San Paulo, BR.
2014. Monoclonal Antibodies. Sírio-Libanês Teaching and Research Institute. San Paulo, BR.
2013. New Mechanisms of Anthracycline-Cardiomyopathy. The Korean Society for Laboratory Medicine. Daegu, KR.
2013. Monitoring of Cardiac Function after Cancer Treatment and Management of Cancer-Associated Cardiac Dysfunction. International Symposium on Supportive Care in Cancer. Berlin, DE.
2013. What medical oncologist need to know about new cardiac drugs in the treatment of cancer patients. Canadian Oncology Network Conference. Ottawa, US.
2012. Keynote Speaker: Bringing Technology and Cardioncology Together The Canadian Cardiac Oncology Network. 2nd Annual Canadian Cardiac Oncology Network, Ottawa, Ontario, Canada, 6/2012. Ottawa, CA.
2010. Evaluating the Biolo0gical Efficacy of Antiplatelet Medication in Cancer Patients: Genotype or Phenotype?. First International Conference on Cancer and the Heart. Houston, US.
2010. Heart Failure to Heart Success : A Patient's Story , The MD Anderson Experience. Invited. First International Conference on Cancer and the Heart. Houston, US.
2010. Detection and Treatment and Natural History of Cardiotoxicity. 65th Brazilian Congress of Cardiology. Belo Horizonte, BR.
2010. New Concepts in Management of Cardiomyopathy for Novel Cancer Therapeutics. 65th Brazilian Congress of Cardiology. Belo Horizonte, BR.
2010. Management of Acute Coronary Syndromes in Oncology Patients. 65th Brazilian Congress of Cardiology. Belo Horizonte, BR.
2009. Management and Treatment of Hypertension. First International Forum of Management of Arterial Hypertension. Casablanca, MA.
2009. Treating Cardiovascular Disease Related to Oncology Therapy. Albert Einstein Onco-Cardiology 1st International Symposium. Sao Paulo, BR.
2009. Acute Coronary Syndrome in the Cancer Patient: There is no safety in numbers. Milan, IT.
2004. Imatinib and Heart Failure: Is there Cause of Concern?. Heart Failure Society of America 8th Annual Scientific Sessions. Toronto, CA.
2000. Updates: Arterial Hypertension. Invited. 4th International Symposium in Primary Medical Care. Monterrey, MX.
1999. Medical and Surgical Management of Congestive Heart Failure. Invited. Monterrey, MX.
1998. Genetic Modulation of Cardiomyopathies. Invited. Berlin, DE.
Cardiotoxicity during Oncology Treatment: Diagnosis and Follow-up. Albert Einstein Onco-Cardiology 1st International Symposium. Sao Paulo, BR.

Formal Peers

2020. Building and Repairing the Heart: Coronary Artery Development and Regeneration. Invited. Housrton, TX, US.
2018. Global Cardio-Onocology Summit. Invited, GB.
2018. Being the CEO of your Professional and Financial Future. Invited, US.
2018. Observations of a Cardiologist Working in a Cancer Center. Invited, US.
2014. CardioOncology: The Birth of a New Medical Specialty. Invited. Hershey, PA, US.
2014. Cardiovascular Toxicities of Anti-Cancer Therapies. Invited. Milwaukee, WI, US.
2013. New Mechanisms of Anthracycline-Cardiomyopathy. Novel Platforms to Identify and treat an old disease. Invited. Daegu.
2013. Cardiotoxicity: Detection, Treatment and Management. Invited. Toronto, CA.
2012. Cardiac Issues in the Breast Cancer survivor. Invited. Falls Church, VA, US.
2011. Chemotherapy-Induced Cardiomyopathy. Invited. Raleigh, NC, US.
2009. Cardiotoxicity: Management and Treatment of New Therapies. Invited. Calgary, CA.
2009. Cardiovascular Effects of Novel Cancer Agents. Invited. Edmonton, CA.
2009. Cardiotoxicity of Novel Tyrosine Kinase Inhibitors. Invited. Vancouver, CA.
2009. Tyrosine Kinase Inhibitors and Cardiovascular Complications. Invited. Quebec, CA.
2009. Cardiotoxicity and Cancer Therapy. Invited. London, CA.
2009. Tyrosine Kinase Inhibitors and Cardiotoxicity. Invited. Halifax, CA.
2009. Prevention and Treatment of Cardiovascular Complications of Tyrosine Kinase Inhibitors. Invited. Hamilton Ontario, CA.
2009. Novel Approaches to Management of Tyrosine Kinase Inhibitors and Cardiovascular Disease. Invited. Toronto, CA.
2009. Chemotherapy-Induced Cardiac Toxicity in the Treatment of breast Cancer. Invited. Waukesha, WI, US.
2008. Management and Treatment of Acute Coronary Syndromes in the Cancer Patient. Invited. New York, NY, US.
2008. Management and Treatment Options for Deep Vein Thrombosis. Invited. New Orleans, LA, US.
2008. Management and Treatment of Anthracycline and Radiation Associated Cardiotoxicity. Invited. Memphis, TN, US.
2008. Management of Cardiac Toxicity in Novel Therapeutics for the Cancer Patient. Invited. Milwaukee, WI, US.
2007. Extreme Makeover: Treatment of Cardiovascular Complications in Pediatric Cancer Survivors. Invited. Memphis, TN, US.
2006. Herceptin: The Cardiology/Oncology Connection. Invited. Los Angeles, CA, US.
2005. Cardiotoxicity in New Therapies for Cancer. Invited. Oak Lawn, IL, US.
2004. Cardiovascular Complications in Cancer Patients: A Clinical Perspective”. Invited. Madison, WI, US.
2003. Treating Cancer and Heart Disease can we do both at the same time?”. Invited. Phoenix, AZ, US.
2002. Hereditary Dilated Cardiomyopathy: Prevalence, Pathogenesis, and Therapy. Invited. New York, NY, US.

Less

Grant & Contract Support

Date:	2016 - 2020
Title:	A Phase I, First in Human, Multicenter, Randomized, Double-Blinded, Placebo Controlled Study of Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced Cardiomyopathy. AKA Stem Cell Injection in Cancer Survivors (SENECA)
Funding Source:	NIH/NHLBI
Role:	Co-PI

Date:	2016 - 2018
Title:	Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients with Recent Onset Anthracycline-Associated Cardiomyopathy 2014-0519
Funding Source:	Texas Medical Center Regenerative Medicine Funding
Role:	Co-PI

Date:	2014 - Present
Title:	Metabolic underpinnings of AL amyloid cardiomyopathy
Funding Source:	NIH/NHLBI
Role:	Collaborator

Date:	2014 - Present
Title:	Discovery of Novel Genetic Predictors of Late Anthracycline Cardiotoxicity in Long-term Childhood Cancer Survivors
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator

Date:	2014 - Present
Title:	ENHANCE Study: Preserving cardiac function in breast cancer survivors
Funding Source:	NIH/NCI
Role:	Collaborator

Date:	2012 - 2016
Title:	Longitudinal Cardiotoxicity in Adult Survivors Childhood Cancer
Funding Source:	NIH/NCI
Role:	CO-I
ID:	1-R01 CA157838-01A1

Date:	2012 - 2017
Title:	Molecular Signatures of Tyrosine Kinase Signaling Proteins and microRNAs for Chemotherapy-Induced Cardiotoxicity
Funding Source:	NIH/NHLBI
Role:	Collaborator

Date:	2009 - 2017
Title:	Long term Effects of Anthracycline Medicated Cardiotoxicity
Funding Source:	St. Jude Children's Hospital
Role:	Collaborator

Date:	2006 - 2025
Title:	Phase I Prevention study of Atorvastin in Women at increased risk of breast cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	N01-CN35159

Date:	2005 - 2007
Title:	MRP: (Multi-Discipline Research Project) Genetic Polymorphisms of Oxidative Stress in Chemotherapy-Induced Heart Failure
Funding Source:	MD Anderson Cancer Center
Role:	Project Leader

Date:	2004 - 2006
Title:	The Use of Nesiritide in the Management of Acute Diastolic Heart Failure,
Funding Source:	Scios Pharmaceuticals
Role:	Principal Investigator-MDACC

Date:	2004 - 2006
Title:	RARE: Reported Atrial Fibrillation Inappropriate Mode Switch in Sick Sinus Syndrome Patients
Funding Source:	St Jude's Medical
Role:	PI

Date:	2003 - 2006
Title:	Phase IV Open labeled study to test the effectiveness of Nesiritide in reversing pulmonary hypertension in patients who will be undergoing cardio thoracic surgery
Funding Source:	Scios Pharmaceuticals
Role:	Collaborator
ID:	2003-0562

Title:	Programmable Bio-Nano-Chip Technology for the Point-of-Care Assessment of Cardiac Toxicity in Breast Cancer Patients Receiving Treatment
Funding Source:	Rice University
Role:	CO-I

Title:	Exploring the role novel Tyrosine Kinase signaling links in Chemotherapy Induced Cardiomyopathy
Funding Source:	NIH/NCI
Role:	Consultant

Title:	Randomized 3-Arm Trial with Standard of Care Alone vs either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) plus Standard of Care in Patients with Recent Onset of Anthracycline-Associated Cardiomyopathy
Funding Source:	Texas Medical Center-Regenerative Medicine
Role:	Co-PI

Title:	Cardiac Contractility Modulator for Anthracycline Cardiomyopathy
Funding Source:	Impulse Dynamics
Role:	Co-PI

Selected Publications

Peer-Reviewed Articles

Karimzad, K, Shah, SJ, Kry, SF, Peeler, CR, Pollard-Larkin, JM, Koduri, A, Chacon Portillo, M, Chauhan, S, Amatullah, A, Miller, C, Strang, A, Song, J, Mir Zaman Shah, K, Lopez, D, Wagner, D, Tsai, J, Vachhani, S, Thakar, DR, Iliescu, C, Durand, J, Dougherty, AH, Kantharia, BK, Deswal, A. Safety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices. Journal of the American Heart Association 14(17), 2025. e-Pub 2025. PMID: 40847479.
Ali, A, Bourdillon, M, Ali, HR, Song, J, Koutroumpakis, E, Jewani, P, Khalaf, SZ, Hamzeh, IR, Kumar, S, Palaskas, NL, Durand, J, Iliescu, C. CardioMEMS guided heart failure management in cardio-oncology patients. Cardio-Oncology 11(1), 2025. e-Pub 2025. PMID: 40682155.
Fatakdawala, M, Ali, HR, Song, J, Irizarry-Caro, JA, Faiz, S, Kumar, S, Yusuf, SW, Durand, J, Iliescu, C, Palaskas, NL, Deswal, A, Koutroumpakis, E. Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer. JACC: CardioOncology 7(4):448-450, 2025. e-Pub 2025. PMID: 40366327.
Palaskas, NL, King, NE, Ostos-Mendoza, KC, Ruiz-Jurado, A, Ali, HR, Koutroumpakis, E, Deswal, A, Iliescu, C, Durand, J, Karimzad, K. Pacing Solutions for Immune Checkpoint Myocarditis and Associated Conduction Disorders. JACC: Case Reports 30(8), 2025. e-Pub 2025. PMID: 40250924.
Groarke JD, Ness KK, Dhaduk R, Plana JC, Durand JB, Luepker RV, Joshi VM, Ehrhardt M, Mulrooney DA, Dixon SB, Nohria A, Green DM, Howell RM, Srivastava DK, Jefferies JL, Robison LL, Hudson MM, Armstrong GT. Autonomic Dysfunction Among Adult Survivors of Childhood Cancer in the St. Jude Lifetime Cohort Study. JACC CardioOncol 6(5):775-787, 2024. e-Pub 2024. PMID: 39479326.
Debover N, Eapen GA, Casal RF, Durand JB, Eisenberg MA, Feldman H, May C, Ali Z, Rice D, Mehran J. Endobronchial Ultrasound: A novel screening test for pulmonary hypertension prior to major pulmonary surgery. Journal of Thoracic and Cardiovascular Surgery Techniques, 2023. e-Pub 2023. PMID: 38352000.
Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, Crago A, Wise-Draper T, Balanchivadze N, Hwang C, Fecher LA, Gomez CG, Hayes-Lattin B, Glover MJ, Shah SA, Gopalakrishnan D, Griffiths EA, Kwon DH, Koshkin VS, Mahmood S, Bashir B, Nonato T, Razavi P, McKay RR, Nagaraj G, Oligino E, Puc M, Tregubenko P, Wulff-Burchfield EM, Xie Z, Halfdanarson TR, Farmakiotis D, Klein EJ, Robilotti EV, Riely GJ, Durand JB, Hayek SS, Kondapalli L, Berg S, O'Connor TE, Bilen MA, Castellano C, Accordino MK, Sibel B, Weissmann LB, Jani C, Flora DB, Rudski L, Dutra MS, Nathaniel B, Ruíz-García E, Vilar-Compte D, Gupta S, Morgans A, Nohria A, Cancer Consortium CA. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Transl Oncol 34:101709, 2023. e-Pub 2023. PMID: 37302348.
Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. PMID: 37016930.
Kim JW, Dayah TJ, Javaid A, Monlezun DJ, Balanescu DV, Donisan T, Karimzad K, Hakeem A, Boone DL, Palaskas N, Lopez-Mattei J, Kim PY, Durand JB, Song J, Balanescu SM, Yang EH, Herrmann J, Marmagkiolis K, Toutouzas K, Johnson NP, Iliescu CA. Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease. Medicina (Kaunas) 58(7), 2022. e-Pub 2022. PMID: 35888603.
Koutroumpakis E, Niku A, Black CK, Ali A, Sadaf H, Song J, Palaskas N, Iliescu C, Durand JB, Yusuf SW, Lee HC, Buja LM, Deswal A, Banchs J. Evaluation of contemporary echocardiographic and histomorphology parameters in predicting mortality in patients with endomyocardial biopsy-proven cardiac AL amyloidosis. Front Cardiovasc Med 9:1073804, 2022. e-Pub 2022. PMID: 36762300.
Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, Durand JB, Deswal A, Zhao B, Maximilian Buja L, Iliescu C. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 23(10):1725-1735, 2021. e-Pub 2021. PMID: 34114291.
Dixon SB, Howell CR, Lu L, Plana JC, Joshi VM, Luepker RV, Durand JB, Ky B, Lenihan DJ, Jefferies JL, Green DM, Ehrhardt MJ, Mulrooney DA, Folse TE, Partin RE, Santucci AK, Howell RM, Srivastava DK, Hudson MM, Robison LL, Ness KK, Armstrong GT. Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort. Cancer 127(3):458-466, 2021. e-Pub 2021. PMID: 33108003.
Baurès R, Fourteau M, Thébault S, Gazard C, Pasquio L, Meneghini G, Perrin J, Rosito M, Durand JB, Roux FE. Time-to-contact perception in the brain. J Neurosci Res 99(2):455-466, 2021. e-Pub 2021. PMID: 33070400.
De Castro V, Smith AT, Beer AL, Leguen C, Vayssière N, Héjja-Brichard Y, Audurier P, Cottereau BR, Durand JB. Connectivity of the Cingulate Sulcus Visual Area (CSv) in Macaque Monkeys. Cereb Cortex 31(2):1347-1364, 2021. e-Pub 2021. PMID: 33067998.
Abdulla A, Durand JB, Lopez-Mattei J, Palaskas N. A Rare Case of Testicular Teratoma Metastasizing to the Right Ventricle. JACC Case Rep 3(1):117-119, 2021. e-Pub 2021. PMID: 34317482.
Goldberg JF, Ness KK, Chi X, Santucci AK, Plana JC, Joshi VM, Luepker RV, Durand JB, Partin RE, Howell RM, Wilson CL, Towbin JA, Jefferies JL, Srivastava DK, Hudson MM, Robison LL, Armstrong GT. Cardiovascular Family History Increases Risk for Late-Onset Adverse Cardiovascular Outcomes in Childhood Cancer Survivors: A St. Jude Lifetime Cohort Report. Cancer Epidemiol Biomarkers Prev 30(1):123-132, 2021. e-Pub 2021. PMID: 33033146.
Kim P, Masha L, Olson A, Iliescu C, Karimzad K, Hassan S, Palaskas N, Durand JB, Leung CH, Lopez-Mattei J. QT Prolongation in Cancer Patients. Front Cardiovasc Med 8:613625, 2021. e-Pub 2021. PMID: 33718445.
Zarifa A, Lopez-Mattei J, Palaskas NL, Iliescu C, Durand JB, Kim PY. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Adv Exp Med Biol 1342:377-387, 2021. e-Pub 2021. PMID: 34972975.
Heidari-Bateni G, Durand JB, Iliescu C, Gladish G, Deswal A, Patel AR, Kim P, Song J, Hassan S, Palaskas N, Baldassarre LA, Bucciarelli-Ducci C, Lopez-Mattei J. Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. Front Cardiovasc Med 8:734820, 2021. e-Pub 2021. PMID: 34765654.
Rivera D, Takahashi K, Durand JB, Ferrajoli A. Ibrutinib-Associated Cardiovascular Events in a Patient Wearing an Implanted Loop Recorder. Mediterr J Hematol Infect Dis 13(1):e2021044, 2021. e-Pub 2021. PMID: 34276913.
Agha AM, Palaskas N, Patel AR, DeCara J, Parwani P, Iliescu C, Durand JB, Kim P, Hassan S, Gladish G, Lee HC, Kaufman GP, Lopez-Mattei JC. Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis. Front Cardiovasc Med 8:626414, 2021. e-Pub 2021. PMID: 34268341.
Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, Pepine CJ, Mitrani RD, Hare JM, Murphy MP, March KL, Ikram S, Lee DP, O'Brien C, Durand JB, Miller K, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Gee AP, Richman S, Taylor DA, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, Simpson LM, Lai D, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD, Network (CCTRN) CCTR. Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. JACC CardioOncol 2(4):581-595, 2020. e-Pub 2020. PMID: 33403362.
Khalil M, Karimzad K, Durand JB, Malek AE, Raad II, Viola GM. Prevention of Cardiac Implantable Electronic Device-Related Infection in Patients With Cancer: The Role of a Comprehensive Prophylactic Bundle Approach That Includes the Antimicrobial Mesh. Open Forum Infect Dis 7(11):ofaa433, 2020. e-Pub 2020. PMID: 33204750.
Balanescu DV, Donisan T, Deswal A, Palaskas N, Song J, Lopez-Mattei J, Kim PY, Durand JB, Doundoua D, Marmagkiolis K, Iliescu C. Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. Int J Cardiol 313:1-8, 2020. e-Pub 2020. PMID: 32320781.
Hayek S, Brinkman TM, Plana JC, Joshi VM, Leupker RV, Durand JB, Green DM, Partin RE, Santucci AK, Howell RM, Srivastava DK, Hudson MM, Robison LL, Armstrong GT, Ness KK. Association of Exercise Intolerance With Emotional Distress, Attainment of Social Roles, and Health-Related Quality of Life Among Adult Survivors of Childhood Cancer. JAMA Oncol 6(8):1194-1202, 2020. e-Pub 2020. PMID: 32584369.
Balanescu DV, Donisan T, Palaskas N, Lopez-Mattei J, Kim PY, Buja LM, McNamara DM, Kobashigawa JA, Durand JB, Iliescu CA. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. Cardiovasc Pathol 47:107211, 2020. e-Pub 2020. PMID: 32268262.
Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc 9(2):e013757, 2020. e-Pub 2020. PMID: 31960755.
Ness KK, Plana JC, Joshi VM, Luepker RV, Durand JB, Green DM, Partin RE, Santucci AK, Howell RM, Srivastava DK, Hudson MM, Robison LL, Armstrong GT. Exercise Intolerance, Mortality and Organ System Impairment in Adult Survivors of Childhood Cancer. J Clin Oncol 38(1):29-42, 2020. e-Pub 2020. PMID: 31622133.
Agha AM, Gill C, Balanescu DV, Donisan T, Palaskas N, Lopez-Mattei J, Hassan S, Kim PY, Charitakis K, Cilingiroglu M, Oo TH, Kroll M, Durand JB, Hirsch-Ginsberg C, Marmagkiolis K, Iliescu C. Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. Front Cardiovasc Med 7:9, 2020. e-Pub 2020. PMID: 32118047.
Zarifa A, Albittar A, Kim PY, Hassan S, Palaskas N, Iliescu C, Durand JB, Lopez-Mattei J. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy. Curr Opin Cardiol 34(4):441-450, 2019. e-Pub 2019. PMID: 31082852.
Tsai E, Mouhayar E, Lenihan D, Song J, Durand JB, Fadol A, Massey M, Harrison C, Basen-Engquist K. Feasibility and Outcomes of an Exercise Intervention for Chemotherapy-Induced Heart Failure. J Cardiopulm Rehabil Prev 39(3):199-203, 2019. e-Pub 2019. PMID: 31022003.
Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, Naing A, Le H, Hassan SA, Karimzad K, Mouhayar E, Kim P, Lopez-Mattei J, Thompson K, Yusuf SW, Iliescu C. Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. Am J Cardiol 123(8):1351-1357, 2019. e-Pub 2019. PMID: 30765065.
Donisan, T, Balanescu, DV, Iliescu, G, Lopez-Mattei, J, Palaskas, NL, Kim, P, Durand, J, Balanescu, SM, Marmagkiolis, K, Iliescu, C. Acute drops in ejection fraction in contemporary cardio-oncology. Revista Romana de Cardiologie 29(2):246-250, 2019. e-Pub 2019.
Iliescu C, Balanescu DV, Donisan T, Giza DE, Muñoz Gonzalez ED, Cilingiroglu M, Song J, Mukerji SS, Lopez-Mattei JC, Kim PY, Palaskas N, Mouhayar EN, Durand JB, Marmagkiolis K. Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia. Am J Cardiol 122(9):1465-1470, 2018. e-Pub 2018. PMID: 30180958.
Donisan T, Balanescu DV, Lopez-Mattei JC, Kim P, Leja MJ, Banchs J, Marmagkiolis K, Herrmann J, Gregoric I, Durand JB, Iliescu CA. In Search of a Less Invasive Approach to Cardiac Tumor Diagnosis: Multimodality Imaging Assessment and Biopsy. JACC Cardiovasc Imaging 11(8):1191-1195, 2018. e-Pub 2018. PMID: 30092973.
Lopez-Mattei J, Iliescu C, Durand JB, Hassan S, Kim P, Sierra-Galan L, Gladish G. The role of cardiac MRI in cardio-oncology. Future Cardiol 13(4):311-316, 2017. e-Pub 2017. PMID: 28639454.
Abu Saleh WK, Ramlawi B, Shapira OM, Al Jabbari O, Ravi V, Benjamin R, Durand JB, Leja MJ, Blackmon SH, Bruckner BA, Reardon MJ. Improved Outcomes With the Evolution of a Neoadjuvant Chemotherapy Approach to Right Heart Sarcoma. Ann Thorac Surg 104(1):90-96, 2017. e-Pub 2017. PMID: 28189277.
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35(8):893-911, 2017. e-Pub 2017. PMID: 27918725.
Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA. Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. Oncoimmunology 6(12):e1361097, 2017. e-Pub 2017. PMID: 29209563.
Iliescu C, Khair T, Marmagkiolis K, Iliescu G, Durand JB. Echocardiography and Fluoroscopy-Guided Pericardiocentesis for Cancer Patients With Cardiac Tamponade and Thrombocytopenia. J Am Coll Cardiol 68(7):771-3, 2016. e-Pub 2016. PMID: 27515340.
Cortes JE, Jean Khoury H, Kantarjian H, Brümmendorf TH, Mauro MJ, Matczak E, Pavlov D, Aguiar JM, Fly KD, Dimitrov S, Leip E, Shapiro M, Lipton JH, Durand JB, Gambacorti-Passerini C. Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. Am J Hematol 91(6):606-16, 2016. e-Pub 2016. PMID: 26971533.
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Konopleva M, Rajkhowa T, Durand M, Andreeff M, Levis M, Cortes J. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 90(4):276-81, 2015. e-Pub 2015. PMID: 25530214.
Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 2015. e-Pub 2015. PMID: 25445468.
Hong, DS, Henary, H, Falchook, GS, Naing, A, Fu, S, Moulder, S, Wheler, JJ, Tsimberidou, AM, Durand, J, Khan, R, Yang, P, Johansen, MJ, Newman, RA, Kurzrock, R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors. Investigational New Drugs 32(6):1204-1212, 2014. e-Pub 2014. PMID: 24919855.
Mulrooney DA, Nunnery SE, Armstrong GT, Ness KK, Srivastava D, Donovan FD, Kurt BA, Metzger ML, Krasin MJ, Joshi V, Durand JB, Robison LL, Hudson MM, Flamm SD. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer 120(22):3536-3544, 2014. e-Pub 2014. PMID: 25041978.
Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs 32(4):717-22, 2014. e-Pub 2014. PMID: 24764123.
Oliveira GH, Mukerji S, Hernandez AV, Qattan MY, Banchs J, Durand JB, Iliescu C, Plana JC, Tang WH. Incidence, predictors, and impact on survival of left ventricular systolic dysfunction and recovery in advanced cancer patients. Am J Cardiol 113(11):1893-8, 2014. e-Pub 2014. PMID: 24837270.
Bickford CL, Agarwal R, Urbauer DL, Durand JB, Lenihan DJ. Efficacy and Safety of Ibutilide for Chemical Cardioversion of Atrial Fibrillation and Atrial Flutter in Cancer Patients. Am J Med Sci 347(4):277-81, 2014. e-Pub 2014. PMID: 23588261.
Yusuf SW, Solhpour A, Banchs J, Lopez-Mattei JC, Durand JB, Iliescu C, Hassan SA, Qazilbash MH. Cardiac amyloidosis. Expert Rev Cardiovasc Ther 12(2):265-77, 2014. e-Pub 2014. PMID: 24386926.
Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, Stovall M, Chow EJ, Sklar CA, Mulrooney DA, Mertens AC, Border W, Durand JB, Robison LL, Meacham LR. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31(29):3673-80, 2013. e-Pub 2013. PMID: 24002505.
Mouhayar E, Durand JB, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf 12(5):687-96, 2013. e-Pub 2013. PMID: 23560546.
Yusuf SW, Sharma J, Durand JB, Banchs J. Endocarditis and myocarditis: a brief review. Expert Rev Cardiovasc Ther 10(9):1153-64, 2012. e-Pub 2012. PMID: 23098151.
Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, Daniel Donovan F, Metzger ML, Arevalo A, Durand JB, Joshi V, Hudson MM, Robison LL, Flamm SD. Screening Adult Survivors of Childhood Cancer for Cardiomyopathy: Comparison of Echocardiography and Cardiac MRI. J Clin Oncol 30(23):2876-84, 2012. e-Pub 2012. PMID: 22802310.
Berri RN, Sahai SK, Durand JB, Lin HY, Folloder J, Rozner MA, Gottumukkala V, Katz MH, Lee JE, Fleming JB. Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy. J Am Coll Surg 214(5):778-87, 2012. e-Pub 2012. PMID: 22440057.
Daher IN, Daigle TR, Bhatia N, Durand JB. The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J 39(2):190-8, 2012. e-Pub 2012. PMID: 22740730.
Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 35(7):443-50, 2012. e-Pub 2012. PMID: 22588943.
Yusuf SW, Cipolla C, Durand JB, Lenihan DJ. Cancer and Cardiovascular Disease. Cardiology Research and Practice, 2011. e-Pub 2011.
Yusuf SW, Sarfaraz A, Durand JB, Swafford J, Daher IN. Management and outcomes of severe aortic stenosis in cancer patients. Am Heart J 161(6):1125-32, 2011. e-Pub 2011. PMID: 21641359.
Yusuf SW, Kim P, Durand JB. Erlotinib or gefitinib for non-small-cell lung cancer. N Engl J Med 364(24):2367; author reply 2368, 2011. e-Pub 2011. PMID: 21675910.
Daher, IN, Banchs, J, Yusuf, SW, Mouhayar, E, Durand, J, Gladish, G. Impact of cardiac computed tomographic angiography findings on planning of cancer therapy in patients with concomitant structural heart disease. Cardiology Research and Practice 1(1), 2011. e-Pub 2011. PMID: 21559257.
Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780, 2011. e-Pub 2011. PMID: 22007339.
Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J 38(3):259-60, 2011. e-Pub 2011. PMID: 21720465.
Huh WW, Jaffe N, Durand JB, Munsell MF, Herzog CE. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion. Pediatr Hematol Oncol 27(7):546-57, 2010. e-Pub 2010. PMID: 20795769.
Armenian SH, Sun CL, Mills G, Teh JB, Francisco L, Durand JB, Wong FL, Forman SJ, Bhatia S. Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 16(8):1138-1144, 2010. e-Pub 2010. PMID: 20197101.
Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH, Panel CT, Steering Committee CBTATFOTNCIID. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102(9):596-604, 2010. e-Pub 2010. PMID: 20351338.
Yusuf SW, Gladish G, Lenihan DJ, Lei X, Durand JB, Swafford J, Daher IN. Computerized Tomographic Finding of Saddle Pulmonary Embolism is associated with High Mortality in Cancer Patients. Intern Med J 40(4):293-9, 2010. e-Pub 2010. PMID: 19220554.
Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J 37(3):336-40, 2010. e-Pub 2010. PMID: 20548817.
Tam A, Ensor JE, Snyder H, Gupta S, Durand JB, Wallace MJ. Image-Guided Drainage of Pericardial Effusions in Oncology Patients. Cardiovasc Intervent Radiol 32(6):1217-26, 2009. e-Pub 2009. PMID: 19472002.
Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, Beahm C, Chen MH, Force T. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2(1):15-25, 2009. e-Pub 2009. PMID: 20376335.
Pacana, CL, Durand, J. The risk of central venous catheter placement ipsilateral to the permanent pacemaker. JAVA - Journal of the Association for Vascular Access 14(1):28-30, 2009. e-Pub 2009.
Yusuf SW, Durand JB, Lenihan DJ, Swafford J. Dextrocardia: an incidental finding. Tex Heart Inst J 36(4):358-9, 2009. e-Pub 2009. PMID: 19693317.
Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J, Champion JC, Durand JB, Lenihan DJ. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112(11):2500-8, 2008. e-Pub 2008. PMID: 18386829.
Woodward WA, Durand JB, Tucker SL, Strom EA, Perkins GH, Oh J, Arriaga L, Domain D, Buchholz TA. Prospective analysis of carotid artery flow in breast cancer patients treated with supraclavicular irradiation 8 or more years previously: no increase in ipsilateral carotid stenosis after radiation noted. Cancer 112(2):268-73, 2008. e-Pub 2008. PMID: 18000801.
Yusuf, SW, Durand, J. Acute myocardial infarction in a patient with thrombocytopenia. American Journal of Oncology Review 6(10):591-595, 2007. e-Pub 2007.
Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy. Blood 110(4)(4):1233-1237, 2007. e-Pub 2007. PMID: 17449798.
Sarkiss MG, Yusuf SW, Warneke CL, Botz G, Lakkis N, Hirch-Ginsburg C, Champion JC, Swafford J, Shaw AD, Lenihan DJ, Durand JB. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 109(3):621-7, 2007. e-Pub 2007. PMID: 17167763.
Yusuf SY, Durand JB, Lenihan DJ. Wrap Beats. Am J Med 120(5):417-419, 2007. e-Pub 2007. PMID: 17466651.
Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24(25):4107-15, 2006. e-Pub 2006. PMID: 16908934.
Yusuf SW, Ali SS, Swafford J, Durand JB, Bodey GP, Chemaly RF, Kontoyiannis DP, Tarrand J, Rolston KV, Yeh E, Raad II, Safdar. Culture-positive and culture-negative endocarditis in patients with cancer: a retrospective observational study 1994-2004. Medicine (Baltimore) 85(2):86-94, 2006. e-Pub 2006. PMID: 16609347.
Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten R, Alroy J, Durand JB, Force. Cardiotoxicity of the chemotherapeutic agent, imatinib mesylate. Nature Medicine 12(8):908-916, 2006. e-Pub 2006. PMID: 16862153.
Ewer M, Vooletich M, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights based on Clinical Course and Response to Medical Treatment. Journal of Clinical Oncology 23(31):7820-7826, 2005. e-Pub 2005. PMID: 16258084.
Wong R, Durand JB, Luna MA, Couriel DR, Gajewski JL. Images in cardiovascular medicine. Constrictive pericarditis in a patient with relapsed acute myelogenous leukemia after allogeneic bone marrow transplantation. Circulation 109(9):e146-9, 2004. e-Pub 2004. PMID: 15007019.
Durand, J. Current guidelines in heart failure management. Ethnicity and Disease 12(1):S1-3-S1-11, 2002. e-Pub 2002. PMID: 11913616.
Li D, Czernuszewicz GZ, Gonzalez O, Tapscott T, Karibe A, Durand JB, Brugada R, Hill R, Gregoritch JM, Anderson JL, Quinones M, Bachinski LL, Roberts R. Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy. Circulation 104(18):2188-93, 2001. e-Pub 2001. PMID: 11684629.
Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure. Chest 120(2):460-6, 2001. e-Pub 2001. PMID: 11502644.
Torre-Amione, G, Young, JB, Durand, J, Bozkurt, B, Mann, D, Kobrin, I, Pratt, CM. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 103(7):973-980, 2001. e-Pub 2001. PMID: 11181472.
Torre-Amione, G, Young JB, Durand JB, Bozkurt B, Kobrin I, Pratt C. Hemodynamic Effects of Tezosentan, an Intravenous Endothelin-1 Receptor Antagonist, in Patients with Class III-IV Congestive Heart Failure. Circulation 103:1844-1850, 2001. e-Pub 2001.
Torre-Amione, G, Stetson SJ, Youker KA, Durand JB, Lakkis NM, Killip D, Entman ML, Nagueh SF, Spencer WH III. Decreased Expression of Tumor Necrosis Factor and Regression of Hypertrophy Following Non-Surgical Septal Reduction Therapy for Patients with Hypertrophic Obstructive Cardiomyopathy. Circulation 103:973-980, 2001. e-Pub 2001.
Abraham, WT, Durand, J, Seger, J, Seger, J, Spencer, W, Killip, D, Becker, K, Stevenson, LW, Sweeney, M, Roberts, L, Brophy, M, Caplan, J, Wong, G, Daniel, E, Brockhaus, J, Rizo-Patron, C, Zias, J, Belco, K, Silver, M, Dia, M, Tischer, J, Wesselhoff, K, Young, JB, Wilkoff, BL, Pryce, J, Shewchik, J, Horn, E, Spotnitz, H, Yushak, M, Medina, N, Ann Kral, M, Delurgio, D, Leon, A, Schmidt, J, Smith, P, O’ Conner, C, Sorrentino, R, Le Loudis, D, Smith, A, Langberg, J, McCullough, P, Schuger, C, Frankovich, D, Lehman, J, Wickemeyer, W, Johnson, WB, Sollinger, B, Greene, J, Yee, R, Finan, J. Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure. Journal of Cardiac Failure 6(4):369-380, 2000. e-Pub 2000. PMID: 11145762.
Durand, JB. The Heart Outcomes Prevention Evaluation Study Investigators, Effects of an Angiotensin-Converting-Enzyme Inhibitor,Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 342:145-153, 2000. e-Pub 2000.
Herrera Garza E, Noon GP, Durand JB, Stetson SJ, Zylicz S, Johnson L, Cano Nino R, Herrera Flores F, Torre-Amione G. Heterotopic heart transplantation: 13-year experience at the Methodist Hospital of the Baylor Medical College]. Arch Inst Cardiol Mex 69(6):526-33, 1999. e-Pub 1999. PMID: 10742849.
Torre-Amione G, Stetson SJ, Youker KA, Durand JB, Radovancevic B, Delgado RM, Frazier OH, Entman ML, Noon GP. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. Circulation 100(11):1189-93, 1999. e-Pub 1999. PMID: 10484539.
Knowlton AA, Kapadia S, Torre-Amione G, Durand JB, Bies R, Young J, Mann DL. Differential expression of heat shock proteins in normal and failing human hearts. J Mol Cell Cardiol 30(4):811-8, 1998. e-Pub 1998. PMID: 9602430.
Spencer WH, 3rd, Zhu DW, Kirkpatrick C, Killip D, Durand JB. Subclavian venogram as a guide to lead implantation. Pacing Clin Electrophysiol 21(3):499-502, 1998. e-Pub 1998. PMID: 9558679.
J-B D. The Pursuit Trial Investigators Clinical Events Committee). Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339:436-443, 1998. e-Pub 1998.
Bachinski LL, Abchee A, Durand JB, Roberts R, Krahe R, Hobson GM. Polymorphic trinucleotide repeat in the MEF2A gene at 15q26 is not expanded in familial cardiomyopathies. Mol Cell Probes 11(1):55-8, 1997. e-Pub 1997. PMID: 9076715.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93(4):704-711, 1996. e-Pub 1996. PMID: 8640999.
Durand JB, Bachinski LL, Bieling BS, Czernuszewicz GZ, Abchee AB, Yu QT, Tapscott T, Hill R, Ifegwu J, Marian AJ, Brugada R, Daiger S, Gregoritch JM, Anderson J, Quinones M, Towbin JA, Roberts R. Localization of the gene responsible for familial idiopathic dilated cardiomyopathy to chromosome 1q32. Circulation 92(12):3387-3389, 1995. e-Pub 1995. PMID: 8521556.
Eleftheriades, EG, Durand, J, Ferguson, AG, Engelmann, GL, Jones, SB, Samarel, AM. Regulation of procollagen metabolism in the pressure-overloaded rat heart. Journal of Clinical Investigation 91(3):1113-1122, 1993. e-Pub 1993. PMID: 8450041.
Eleftheriades E, J-B D, Ferguson A, Engelmann G, Jones S, Samarel A. Regulation of procollagen metabolism In the pressure-overloaded rat heart. J Clin Invest 91:1113-1122, 1993. e-Pub 1993.
Blumberg MS, Moltz H. Hypothalamic temperature and the 22 kHz vocalization of the male rat. Physiol Behav 40(5):637-40, 1987. e-Pub 1987. PMID: 3671529.

Invited Articles

Yusuf SW, Durand JB. Management of heart failure in the elderly. Am J Med 118(12):1446, 2005. e-Pub 2005. PMID: 16378818.
Giesler G, Lenihan DJ, Durand JB. The update on the rationale, use and selection of beta-blockers in heart failure. Curr Opin Cardiol 19(3):250-3, 2004. e-Pub 2004. PMID: 15096958.
Durand JB. Heart failure management in African Americans: meeting the challenge. J Clin Hypertens (Greenwich) 6(4 Suppl 1):42-7, 2004. e-Pub 2004. PMID: 15073466.
Ewer, MS, Durand JB, Vooletich M. Perspectives on Chemotherapy-related Cardiotoxicity,. Oncology Forum 6:2-4, 2003. e-Pub 2003.
Durand JB. Current Guidelines in Heart Failure Management. Ethnicity and Disease 12:S-3-S1-11, 2002. e-Pub 2002.
Koerner MM, Durand JB, Lafuente JA, Noon GP, Torre-Amione G. Cardiac transplantation: the final therapeutic option for the treatment of heart failure. Curr Opin Cardiol 15(3):178-82, 2000. e-Pub 2000. PMID: 10952425.
Herrera Garza E, Cubillos Garzon A, Stetson SJ, Cano Nino R, Herrera Flores F, Durand JB, Torre Amione G. Tumor necrosis factor-alpha: a mediator in the pathogenesis of cardiac insufficiency. Arch Inst Cardiol Mex 69(5):462-8, 1999. e-Pub 1999. PMID: 10640210.
Durand JB. Genetic basis of cardiomyopathy. Curr Opin Cardiol 14(3):225-9, 1999. e-Pub 1999. PMID: 10358794.
Durand JB, O'Connell J, Costanzo-Nordin MR. Specific Heart Muscle Diseases. Current Science 7:445-446, 1992. e-Pub 1992.

Review Articles

Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KM. Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol 11:625707, 2021. e-Pub 2021. PMID: 33614514.
Zarifa A, Lopez-Mattei J, Palaskas N, Iliescu C, Durand JB, Kim PY. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. Adv Exp Med Biol 1244:277-285, 2020. e-Pub 2020. PMID: 32301022.
Agha A, Zarifa A, Kim P, Iliescu C, Gladish G, Hassan S, Palaskas N, Durand JB, Lu Y, Lopez-Mattei J. The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics. Methodist Debakey Cardiovasc J 15(4):258-266, 2019. e-Pub 2019. PMID: 31988686.
Palaskas N, Thompson K, Gladish G, Agha AM, Hassan S, Iliescu C, Kim P, Durand JB, Lopez-Mattei JC. Evaluation and Management of Cardiac Tumors. Curr Treat Options Cardiovasc Med 20(4):29, 2018. e-Pub 2018. PMID: 29556752.
Zarifa, A, Salih, M, Lopez-Mattei, J, Lee, HJ, Iliescu, C, Hassan, SA, Palaskas, NL, Durand, J, Mouhayar, E, Kim, J, Kim, P. Cardiotoxicity of fda-approved immune checkpoint inhibitors. Journal of Immunotherapy and Precision Oncology 1(2):68-77, 2018. e-Pub 2018.
Agha AM, Parwani P, Guha A, Durand JB, Iliescu CA, Hassan S, Palaskas NL, Gladish G, Kim PY, Lopez-Mattei J. Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. Open Heart 5(2):e000881, 2018. e-Pub 2018. PMID: 30305910.
Giza DE, Marmagkiolis K, Mouhayar E, Durand JB, Iliescu C. Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective. Curr Cardiol Rep 19(6):56, 2017. e-Pub 2017. PMID: 28484995.
Fadol, AP, Adornetto-Garcia, D, Shelton, V, Durand, J, Yeh, E, Summers, BL. Heart success program. Progress in Pediatric Cardiology 39(2):99-105, 2015. e-Pub 2015.
Yusuf, SW, Ilias-Khan, NA, Durand, J. Chemotherapy-induced cardiomyopathy. Expert Review of Cardiovascular Therapy 9(2):231-243, 2011. e-Pub 2011. PMID: 21506294.
Bathina JD, Daher IN, Plana JC, Durand JB, Yusuf SW. Acute myocardial infarction associated with nonbacterial thrombotic endocarditis. Tex Heart Inst J 37(2):208-12, 2010. e-Pub 2010. PMID: 20401296.
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25):3122-31, 2004. e-Pub 2004. PMID: 15226229.
Ewer, MS, Durand, J, Vooletich, MT. Perspectives on chemotherapy-related cardiotoxicity. Oncology Forum 6(2):2-4, 2003. e-Pub 2003.
Durand JB, Abchee AB, Roberts R. Molecular and clinical aspects of inherited cardiomyopathies. Ann Med 27(3):311-320, 1995. e-Pub 1995. PMID: 7546620.
Durand, J, O'Connell, JB, Costanzo-Nordin, MR. Specific heart muscle disease. Current opinion in cardiology 7(3):445-456, 1992. e-Pub 1992.

Professional Educational Materials

Durand, JB, Fadol A, Heaton A, Woods M. Heart Success: A Resource Guide of Cancer Patients Living with Congestive Heart Failure. MD Anderson Cancer Center, 2003.

Editorials

Yusuf, SW, Cipolla, C, Durand, J, Lenihan, DJ. Cancer and cardiovascular disease. Cardiology Research and Practice 1(1), 2011. PMID: 21904686.

Abstracts

Guerra Rubi O.A., Song J., Palaskas N., Faiz S., Sheshadri A., Kumar S., Mouhayar EN, Durand J, Mehran R., Mitchell K., Deswal A., Rajaram R., Ali HJ. PULMONARY HYPERTENSION POST-MAJOR LUNG RESECTION: INCIDENCE AND RISK FACTORS. ACC 2026. e-Pub 2026.
Abdulla A, Durand JB, Lopez-Mattei J, Palaskas N. A Rate Case of Germ Cell Tumor Metastasizing to the Right Ventricle. American College of Cardiology Scientific Sessions:1217-216, 2020. e-Pub 2020.
Armstrong G, Hudson M, Ness K, Joshi V, Green D, Ky B, Lenihan D, Plana JC, Durand JB, Hudson M. Serum Biomarkers for Detection of Cardiomyopathy in Survivors of Childhood Cancer: A Report from the ST. Jude Lifetime Cohort. NASLCCC, 2020. e-Pub 2020.
Agha A, Gill C, Balanescu D, Donisan T, Boone D, Song J, Iliescu G, Palaskas N, Lopez-Mattei J, Kim P, Doundoua D, Marmagkiolis K, Durand JB, Iliecu C. Coronary Angiography Among Cancer Patients: Determining a Safe Platelet Threshold. American College of Cardiology Scientific Sessions:1250-006, 2020. e-Pub 2020.
Iliescu C, Balanescu DV, Song J, Palaskas NL, Karimzad K, Kim P, Lopez-Mattei J, Durand JB, Jipescu D, Gonzalez EDM, Ntim W, Balanescu SM, Marmagkiolis K, Cilingiroglu M, Donisan T. Early Dual Antiplatelet Therapy Discontinuation in Cancer Patients with Newer Generation Drug-Eluting Stents: A Single-Center Experience. American College of Cardiology Scientific Sessions, 2019. e-Pub 2019.
McDermott L, Laeeq R, Palaskas N, Moudgil R, Kim P, Syed Y, Hassan S, Banchs J, Donisan T, Balanescu D, Iliescu C, Durand JB, Lopez-Matttei J. Using Dobutamine Stress Echocardiograpy to Predict the Recovery of Left Ventricular Function in Cancer Patients Receiving Chemotherapy. American College of Cardiology Scientific Sessions:1271-321, 2019. e-Pub 2019.
Upadhyay A, Lopez- J, Kim P, Iliescu C, Durand JB, Palaskas N, Hassan S, Thompson K, Mouhayar. Diagnostic Performance of High Sensitivity Troponin in Cancer Patients. American College of Cardiology Scientific Sessions:1275-380, 2019. e-Pub 2019.
Zarifa A, Kim PY, Gilchrist S, Iliescu C, Almazor-Suarez M, Lopez-Mattei J, Balanescu DV, Donisan T, Palaskas N, Upadhyay A, Moudgil R, Zhao B, Buja M, Durand JB. Expression of T-Cell Populations and Molecular Markers of Human Myocardium with Checkpoint-Induced Myocarditis. American Society of Clinical Oncology, Immunotherapy-SITI, 2018. e-Pub 2018.
Iliescu CR, Yusuf SW, Iliescu G, Vejpongsa P, Durand JB, Mouhayar E, Cilingiroglu M, Marmagkiolis K. Impact of Chronic Thrombocytopenia In Patients With Coronary Artery Disease And Cancer. Journal of the American College of Cardiology, 2015. e-Pub 2015.
Fadol A, Banchs J, Hassan S, Durand JB, Shelton VD, Fellman B, Yeh ET. Can Medications Be Safely Withdrawn in Patients With Chemotherapy-induced Heart Failure With Recovered Heart Function?. J Cardiac Failure 20(8):Supp, Pg S5, 2014. e-Pub 2014.
Cortes JE, Kantarjian HM, Khoury HJ, Brümmendorf TH, Conlan MG, Wang K, Fly KD, Shapiro M, Lipton JH, Durand J, Gambacorti-Passerin C. Long-Term Assessment of Cardiac Toxicity in Patient with PH+ Leukemias treated with Bosutinib. J Clin Oncol (suppl; abstr 7060):32:5s, 2014. e-Pub 2014.
Manoukian G, Mouhayar E, LeBeau J, Iliescu G, Tomakin G, Hassan S, Banchs J, Yusuf SW, Durand JB, Iliescu C. Cardiac tamponade in cancer patients with severe thrombocytopenia-management and outcomes. Society of Cardiovascular Angiography and Interventions Scientific Sessions, 2013. e-Pub 2013.
LeBeau JT, Silva G, Frusina S, Agarwal M, Iliescu G, Tomakin G, Manoukian G, Banchs J, Kim P, Hassan S, Durand JB, Iliescu C. Optical Coherence Tomography-Guided Antiplatelet Therapy. Journal of the American College of Cardiology, 2013. e-Pub 2013.
Mukerji S, Iliescu G, Yusuf SW, Banchs J, Durand JB, Tomakin G, Iliescu C. Impact of Chronic Thrombocytopenia in Patients with Coronary Artery Disease and Cancer. Catheterization and Cardiovascular Interventions 79 suppl(6):S51, 2012. e-Pub 2012.
Mukerji S, Iliescu G, Yusuf SW, Banchs J, Durand JB, Tomakin G, Iliescu C. Impact of Chronic Thrombocytopenia in Patients with Coronary Artery Disease and Cancer. Journal of the American College of Cardiology 59(13):E1819, 2012. e-Pub 2012.
Mukerji S, Iliescu G, Yusuf SW, Banchs J, Durand JB, Tomakin G, Iliescu C. Impact of Chronic Thrombocytopenia in patients with Coronary Artery Disease and Cancer. Journal of the American College of Cardiology 59(13):E1819, 2012. e-Pub 2012.
Karimzadehnajar K, Azpura F, Shezad S, Durand JB, Iliescu C. Fractional Flow Reserve: Less is sometimes more in cancer patients. Society for Cardiovascular Angiography and Interventions Scientific Sessions, 2011. e-Pub 2011.
Satya K, Parasher P, Stephens M, Reyes M, Durand JB, Iliescu C. Left Main Disease: Therapeutic Strategies in Cancer Patients. Society for Cardiovascular Angiography and Interventions Scientific Sessions, 2011. e-Pub 2011.
Iliescu C, Reyes M, Abi Aad SB, Banchs J, Mouhayar E, Leja M, Daher I, Yusuf W, Durand JB. Clinical Features and Outcomes of Stress-Induced Cardiomyopathy in Cancer Patients. JACC 57(17), 2011. e-Pub 2011.
Henary HA, Kurzrock R, Falchook GS, Naing A, Moulder SL, Wheler JJ, Tsimberidou AM, Durand J, Yang P, Johansen MJ, Newman R, Khan R, Patel U, Hong DS. Final results of a first-in-human phase I trial of PBI-0524, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. J Clin Oncol 29(suppl;abstr 3023), 2011. e-Pub 2011.
Rodriguez MA, Durand J, Astrow AB, Bury MJ, Fanale MA, Hagemeister FB, Huang X, McLaughlin HP, Neelapu SS, Pro B, Kwak LW, Fayad L, Romaguera JE, Younes A, Fisch M. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 29(suppl;abstr 8053), 2011. e-Pub 2011.
Armstrong GT, Chen Y, Kawashima T, Sklar CA, Mulrooney DA, Chow EJ, Border W, Durand J, Mertens A, Stovall M, Leisenring W, Yasui Y, Robison LL. Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 29(suppl;abstr 9507), 2011. e-Pub 2011.
Armstrong G, Ness K, Nolan, V, Green, D, Joshi V, Hudson M, Robison L, Srivastava D, Durand JB. Myocardial Strain for Detection of treatment related cardiac toxicity in adult survivors of pediatric cancer. Pediatric Blood and Cancer 55(5):941, 2010. e-Pub 2010.
Armenian S, Sun CL, Mills G, Shannon T, Francisco L, Wong FL, Durand JB, Forman S, Bhatia S. Predictors of therapy-related congestive heart failure (CHF) following hematopoietic cell transplantation (HCT). Journal of the American College of Cardiology 55(10A):A23.E219, 2010. e-Pub 2010.
Khakoo AY, Massey M, Chua C, Chiu A, Mouhayar E, Durand JB, Lenihan DJ. Hypertension, potentially leading to heart failure, associated with anti-vascular endothelial growth factors therapy can be predicted by baseline risk factors and serical B-type natriuretic peptide levels during treatment. Journal of Cardiac Failure (Abstracts from the 13th Annual Scientific Meeting Heart Failure Society of America) 15(6 Supplement), 2009. e-Pub 2009.
Bidyasar S, Kurzrock R, Falchook GS, Naing A, Wheler JJ, Durand JB, Yang P, Johansen MJ, Newman RA, Khan R, Hong D. A first-in-human phase I trial of PBI-05204 (oleandrin), an inhibitor of Akt, FGF-2, NF-Kb, and p70S6Kin advanced solid tumor patients. Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 27(15S ( May 20 Supplement)):3537, 2009. e-Pub 2009.
Rodriguez MA, Wei W, Huang X, Fisch M, Durand JB. Evaluation of brain natriuretic peptide (BNP, troponin levels, and left ventricular ejection fraction (LVEF)in older adults with diffuse large B cell lymphoma (DLBCL). Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post Meeting Edition) 27(15S May Supplement):e19506, 2009. e-Pub 2009.
Shukla A, Yusuf SW, Daher I, Zhou X, Iliescu C, Lenihan D, Durand JB. Deleterious Effects on Ejection Fraction upon Withdrawal of ACE Inhibitors and Beta-Adrenergic Blockers in Patients with Anthracycline Associated Cardiomyopathy. American College of Cardiology Scientific Sessions, Orlando, Florida, 2009. e-Pub 2009.
Shukla A, Yusuf W, Daher I, Durand JB. High Mortality rates are associated with withdrawal of Beta Blockers and Ace Inhibitors in chemotherapy-induced heart failure. American Heart Association, 2008. e-Pub 2008.
Lenihan DJ, Massey MM, Chua CA, Chiu A, Yusuf SW, Daher I, Durand JB. Clinical Characteristics and Improvement in Systolic Dysfunction in patient with Chemotherapy-Related Heart Failure. Journal of Cardiac Failure 14(6 Supplement 1):S113, 2008. e-Pub 2008.
Rodriguez MA, Fanale M, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Kwak L, Le F, Durand JB. Activity and toxicity of pegylated doxorubicin in combination regimen (DRCOP) for patients less than 60 years old with untreated diffused large B cell lymphoma (DLBCL) A Phase II Study. Journal of Clinical Oncology 26, 2008. e-Pub 2008.
Ater J, Spelman A, Xu A, et al DJ. Cardiotoxicity in at Risk Survivors of Childhood Cancer. Conference Proceedings, 10th International Conference on Longterm Complications of Treatment of Children and Adolescents for Cancer, 2008. e-Pub 2008.
Lenihan DJ, Massey MR, Baysinger KB, Adorno CL, Wareke CL, Steinert D, Fayad L, Plana JC, Yusuf SW, Chiu A, Durand JB, Yeh, ET. Superior Detection of Cardiotoxicity during Chemotherapy Using Biomarkers. Journal of Cardiac Failure 13(6) Supplement 2:S151, 2007. e-Pub 2007.
et al KA. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other patients receiving imatinib mesylate therapy. American Society of Clinical Oncology, 2007. e-Pub 2007.
Shaik N, S Wamique Yusuf S, Woods M, Fadol A, Tong AT, Rozner M, Swafford J, Champion CJ, Lenihan D, Durand J. Cancer Patients with Pre-Existing Heart Failure: Cardiac Resynchronization Therapy Provides a Bridge to Treatment of Highly Treatable Tumors. Journal of Cardiac Failure 12(6):S105, 2006. e-Pub 2006.
Agarwal R, Bickford C, Durand JB, Lenihan D. Heart Failure Patients with New onset atrial fibrillation can be safely and effectively cardioverted with Ibutilide despite concurrent amiodarone therapy. Journal of Cardiac Failure 12(6):S(64), 2006. e-Pub 2006.
Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Boehnke-Michaud L, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long term cardiac tolerability of trastuzumab in HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 24(18S), 2006. e-Pub 2006.
Salcedo P, Shpall E, Yusuf S, Roberson M, Woods M, Lenihan D, Durand JB. Acute heart failure in bone marrow transplantation: Impact of intravenous immune globulin as adjuvant therapy. Journal of Clinical Oncology, 2006. e-Pub 2006.
Herzog CE, Huh WH, Jaffe N, Durand JB. Comparison of doxorubicin cardiotoxicity in pediatric patients when given with dexrazoxane versus as a continuous infusion. Journal of Clinical Oncology 24(18S) Supplement, 2006. e-Pub 2006.
Fadol A, Taubert J, Holm M, Fulton S, Woods M, Zalphour A, Durand JB, Swafford J, Lenihan D. Heart Success Program: Management of Cancer Patients with Heart Failure Through Collaborative Practice. MDACC Research Retreat, 2006. e-Pub 2006.
Agarwal, R, Tong A, Yusuf, SW, Wells R, Jaffe N, Burrer N, Herzog C, Lotlikar S, Iliescu C, Woods M, Vooletich M, Divikaran V, Lenihan D, Towbin J, Durand JB. Carvedilol and Ace-Inhibitors for Early and Late Onset Anthracycline-Induced Heart Failure in Pediatric Oncology Patients. Heart Failure Society of America, 2005. e-Pub 2005.
Grazette LP, Kerkela R, Patten R, Rozenweig A, Durand JB, Force T. Imatinib Mesylate (Gleevec) Induces Mitochondrial Dysfunction and Caspase Activation in Cardiac Myocytes. Journal of Cardiac Failure 11(6) Supplement:S126, 2005. e-Pub 2005.
Tong A, Durand JB, Lenihan D, Rozner M, Vooletich M, Reece A. Hemodynamic Improvement in Acutely Decompensated Diastolic Heart Failure with Nesiritide Infusion. Journal of Cardiac Failure 11(6) Supplement:S107, 2005. e-Pub 2005.
Yusuf, SW, Ali S, Tong A, Swafford J, Durand JB, Kontoyiannis DP, Rolston KV, Raad II, Safdar A. Clinical spectrum of endocarditis in patients with cancer: a case-control evaluation of culture-positive and culture-negative disease, 1994-2004. 15th European Congress of Clinical Microbiology & Infectious Diseases:A-1382, 2005. e-Pub 2005.
Shaik, N, Yusuf SW, Tong A, Woods M, Divikaran V, Lotlikar S, Lenihan D, Durand JB. The Role of Valsartan and Carvedilol for Treatment of Acr-Intolerant Chemotherapy Associated Cardiomyopathy. Heart Failure Society of America, 2005. e-Pub 2005.
Lenihan, D, Vooletich M, Isabel, J, Davis J, Tong A, Durand JB. Nesiritide May be Valuable in the Evaluation and Treatment of Secondary Pulmonary Hypertension. Heart Failure Society of America, 2005. e-Pub 2005.
Iliescu, C, Yusuf SW, Auerbach L, Tong A, Vooletich M, Cortez J, Divikaran V, Lotlikar S, Woods M, Talpaz M, Lenihan D, Kantarjian H, Force T, Durand JB. Impact of Ace-Inhibitors and Carvedilol on Recovery of Cardiac Function in Imatinib Associated Cardiomyopathy. Heart Failure Society of America, 2005. e-Pub 2005.
Fadol, A, Taubert J, Holm M, Fulton S, Woods M, Durand JB, Lenihan D. Heart Success Program: Management of Cancer Patients with Heart Failure Through Collaborative Practice. Heart Failure Society of America, 2005. e-Pub 2005.
Yocum GT, Khakoo AY, Read EJ, Frank J, and Arbab AS. Differentiation of Ferumoxides-Protamine Sulfate Complexes Labeled Human Hematopoeitic and Mesenchymal Stem Cells. Society for Molecular Imaging Meeting, 2004. e-Pub 2004.
Tong, A, Lenihan D, Durand JB. Nesiritide is Effective in the Management of Acute Diastolic Heart Failure. Journal of Cardiac Failure, 2004. e-Pub 2004.
Ewer, MS, Vooletich MT, Woods M, Durand JB, Lenihan DJ. Reversibility of Trastuzumab-Induced Congestive Heart Failure in Patients Previously Treated with Anthracyclines. Journal of Cardiac Failure, 2004. e-Pub 2004.
Lenihan, D, Tong, A Divikaran V, Yusuf SW, Fadol A, Pai S, Tristan J, Campana R, Vooletich M, Giesler G, Theriault R, Valerio V, Ewer M, Swafford J, Durand JB. Trastuzumab (T) (Herceptin)- Associated Cardiomyopathy: Sequential Stress and Response to Ace-Inhibitors and Carvedilol . Journal of Cardiac Failure 9:383, 2003. e-Pub 2003.
Tong, A, Lenihan D, Tristan J, Durand JB. Brain Natriuretic Peptide (BNP) is Useful as a Biochemical Predictor of Contractile Reserve During Dobutamine Stress Echocardiogram. Journal of Cardiac Failure 9:361, 2003. e-Pub 2003.
Lenihan, D, Tong A, Woods M, Yusuf SW, Fadol A, Pai S, Tristan J, Campana R, Vooletich M, Giesler G, Divikaran V, Swafford J, Ewer M, Durand JB. Withdrawal of Ace-Inhibitors and Beta Blockers in Chemotherapy Induced Heart Failure Leads to Severe Adverse Cardiovascular Events. Circulation 108:665, 2003. e-Pub 2003.
Newsome, E, Woods M, Swafford J, Zito R, Gibbs H, Ewer, MYusuf, S, Centenio, J, Woods M, Pai S, Fadol A, Vooletich M, Yeh E, Durand JB. Toxic Stunning: Carvedilol for Recovery of Heart Function in Patients with Chemotherapy-Induced Congestive Heart Failure. J Cardiac Fail 8:080, 2002. e-Pub 2002.
Sarkiss, M, Simchowitz, B, Swafford J, Zito R, Gibbs H, Ewer, MYusuf, S, Centenio, J, Woods M, Pai S, Fadol A, Vooletich M, Yeh E, Durand JB. Acute Coronary Syndromes and Thrombocytopenia in The Cancer Patient are Associated with High Mortality Rates. SCA & I, 2002. e-Pub 2002.
Woods, M, Swafford J, Zito R, Gibbs H, Ewer M, Yusuf S, Centenio J, Woods M, Pai S, Fadol A, Vooletich M, Yeh E, Durand JB. Milrinone and Carvedilol in Medical Management of Chemotherapy-Induced Acute Decompensated Class IV Heart Failure. J Cardiac Fail 8:296, 2002. e-Pub 2002.
Li, D, Czernuszewicz G, Gonzalez O, Tapscott T, Karibe A, J-B D, Brugada R, Hill R, Gregoritch J, Anderson JL, Quinones M, Bachinski LL, Roberts R. Dilated Cardiomyopathy caused by a novel Mutation in Cardiac Troponin T Gene. Circulation 104, 2001. e-Pub 2001.

Book Chapters

Yeh, ET, et al DJ. In: MD Anderson Practices in Onco-Cardiology, 2016.
Woods M, Bickford C, Pataki L, Cheatam C, Durand JB. High Blood Pressure and You. In: Treating High Blood Pressure After Cancer Treatment, 2012.
Mejevoi N, Durand JB, Cohen M. Patients with Impaired Hemostasis Requiring Cardiac Catheterization and Coronary Intervention. In: Common Clinical Dilemmas in Percutaneous Coronary Interventions, 65-76, 2007.
Durand JB, Fadol A, Heaton A, Woods M. In: Heart Success: A Resource Guide of Cancer Patients Living with Congestive Heart Failure, 2003.
Ewer, M, Durand JB, Swafford J, Yusuf SW. Emergency Cardiac Problems in the Cancer Patient. In: Oncological Emergencies(Holland Prei ). DC Decker Inc, 305-314, 2002.

Less

CV information above last modified August 21, 2026

Jean-Bernard Durand, MD, FACC, FACP, FCCP, FHFSA, FAHA, FHRS, FESC

About Dr. Jean-Bernard Durand

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Editorials

Abstracts

Book Chapters

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Jean-Bernard Durand, MD, FACC, FACP, FCCP, FHFSA, FAHA, FHRS, FESC

About Dr. Jean-Bernard Durand

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Professional Educational Materials

Editorials

Abstracts

Book Chapters

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson